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In the last decades of the twentieth century, treatment of patients with coronary 
artery disease has changed dramatically. After the introduction in 1977 by 
Andreas Gruentzig [1], the importance of percutaneous coronary interventions 
(PCI) in the treatment of patients with coronary artery disease is still rising, with 
beneficial effects on both morbidity and mortality. Balloon angioplasty was the 
principal mode of performing PCI in the first years. Nowadays (drug-eluting) stent 
implantation is mostly performed. Stent implantation is effective in the 
management of (iatrogenic) coronary dissection during PCI and reduces 
restenosis [2-4]. Other techniques of PCI such as cutting balloon or atherectomy 






































 Figure 1. Number of PCI in the Netherlands throughout the years (7). 
 
As in many other countries, in the Netherlands the number of PCIs has increased 
rapidly (figure 1) [7]. In 2007, nearly 35,000 PCIs were performed, whereas a 
number of more than 40,000 interventions has been postulated for 2010 [8]. Only 
a part of this rise can be explained by the use of PCI instead of coronary artery 
bypass grafting (CABG). Another important explanation is the more invasive 
approach of patients with acute coronary syndromes (ACS), especially ST-
elevation myocardial infarction (STEMI). 
As the number of PCIs is growing, quality control and the monitoring of efficacy as 
well as safety is of growing importance. Markers of complications of PCI can be 
helpful to identify patients needing more aggressive or different additional 
therapy. Furthermore, these markers can be helpful in improving PCI success, by 
validating new techniques and medications around PCI directly, instead of 
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awaiting long-term clinical effects for every new therapy. One manner of 





Cardiac enzymes have been shown to be strongly related with myocardial injury, 
infarct size and prognosis in patients with acute myocardial infarction (MI) [9,10]. 
Especially tests for creatine kinase (CK) and tests for the muscle-brain dimer CK-
MB are used throughout the world to diagnose MI for many years [11,12]. 
However, cardiac troponins have been shown to be superior in establishing 
diagnosis and prognosis in patients with suspected ACS [13-15]. Therefore, 
nowadays, the troponins are the preferred biomarkers to diagnose MI, according 
to the most recent definition of MI [16]. The time course of elevations of the 
different serum biomarkers after MI are shown in figure 2 (adapted from 
Braunwald [17]). 
 































PCI for stable angina 
Elevations of cardiac enzymes can be observed frequently after (elective) PCI, 
with reported rates between 6 and 48%, and have been associated with cardiac 
events during follow-up. This has been demonstrated in particular for elevations 
of CK and CK-MB [18-21]. As the diagnostic value of troponin is superior 
compared to CK(-MB) in patients with (suspected) ACS, the prognostic value of 
troponin elevation after PCI, compared to CK(-MB), may be superior as well. 
However, conflicting results are reported about the association between troponin 
elevation and cardiac events and/or mortality during follow-up [21-23]. 
 
PCI for ST-elevation myocardial infarction 
The association between cardiac enzymes, infarct size and mortality during 
follow-up was demonstrated in patients undergoing no reperfusion therapy or 
thrombolysis for STEMI. However, primary PCI has become the preferred therapy 
of patients with STEMI, provided the procedure is performed in a timely manner 
by experienced operators [5,6,24,25]. As reperfused hearts might release cardiac 
enzymes in the systemic circulation in different levels and time courses, the 
predictive values of the enzymes might differ in these patients compared to those 
undergoing no or less effective reperfusion therapy [26]. 
 
PCI for other acute coronary syndromes 
The number of PCI performed in patients with non-STEMI and/or unstable angina 
forms a substantial part of the total number of PCI, and it is expected to be the 
most frequent indication for PCI in the near future in the Netherlands [8]. Patients 
with non-ST-elevation ACS have an adverse prognosis, even when treated with 
early PCI, possibly because of both delayed time-to-hospital arrival and increased 
door-to-balloon time [27,28]. Although a lot of studies on patients undergoing PCI 
for non-ST-elevation ACS have been published [29-32], only few studies report on 
enzyme release after PCI in these patients. Moreover, these studies have 




The main objective of the studies presented in this thesis is to investigate the 
clinical value of cardiac biomarkers after PCI, especially troponin T (TnT), CK and 
CK-MB. The importance of these biomarkers is evaluated in patients undergoing 
elective PCI as well as in patients undergoing primary PCI for STEMI. 
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Part I of this thesis is focused on myocardial injury after elective PCI. 
The second chapter describes the results of a prospective study on 713 
unselected patients undergoing elective PCI, investigating the prognostic 
importance of postprocedural elevation of either TnT or CK. 
The influence of pre-treatment with clopidogrel on myocardial necrosis after 
elective PCI, defined by small postprocedural TnT elevation, is assessed in the 
prospective observational study including 656 patients described in the third 
chapter. 
In the fourth chapter, differences in TnT elevation between multivessel and 
single-vessel PCI are studied in the same cohort as described in chapter 2. 
Furthermore, differences in cardiac events during follow-up are investigated, 
according to the type of index-PCI. 
The fifth chapter is a review of the currently available data with regard to the 
prognostic value of troponin elevation after elective PCI. The association between 
postprocedural troponin elevation and mortality and/or myocardial infarction 
during follow-up is investigated in this meta-analysis, involving 15,581 patients. 
 
Part II of this thesis is focused on myocardial injury around primary PCI. 
In the sixth chapter, the value of TnT on admission in patients with STEMI is 
investigated. The predictors of elevated TnT on admission and its prognostic 
value are evaluated in this study in 444 patients undergoing primary PCI. 
In chapter 7 and 8, the findings of 14 years of primary PCI experience in Zwolle 
are presented. All 4,990 patients are studied in chapter 8, whereas patients who 
died within 2 days after PCI were excluded in chapter 7. 
The prognostic values of CK and CK-MB are investigated in 4,670 patients 
undergoing primary PCI for STEMI in the seventh chapter. The association 
between peak-CK and peak-CK-MB levels, left ventricular function and one-year 
follow-up is assessed. 
The predictive values of long-term mortality of infarct location, enzymatic infarct 
size and LV ejection fraction are compared in the eighth chapter. Whether infarct 
location is an independent predictor of prognosis, even after correction for 
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Background: The prognostic importance of elevated cardiac enzymes after 
elective percutaneous coronary intervention has been debated. Therefore, we 
performed a prospective observational study to evaluate the prognostic value of 
postprocedural rise of troponin T and creatine kinase. 
 
Methods: Troponin T (cut-off value 0.05 ng/ml) and creatine kinase (cut-off value 
180 IU/l with muscle-brain fraction >4%) were measured 12 hours after elective 
percutaneous coronary intervention in 713 consecutive patients without elevated 
troponin before the procedure. Primary endpoint was the combined incidence of 
death, myocardial infarction, stroke, repeat angiography or re-admission because 
of anginal symptoms during the follow-up period. 
 
Results: Troponin was elevated after the procedure in 150 patients (21%) and 
creatine kinase in 66 pts (9%), with a strong association between increased 
troponin and creatine kinase. After a mean follow-up of 10.9 months, mortality 
was low (1%) and not associated with increased troponin or creatine kinase. 
There was, however, a strong relation between postprocedural troponin and re-
admission for angina (p=0.001) or myocardial infarction (p=0.001). Furthermore, 
troponin rise was significantly associated with an increased risk of the primary 
endpoint (relative risk 1.55 95% confidence interval 1.01-2.38). After multivariate 
analysis, troponin elevation but not increased creatine kinase was associated with 
an increased risk of the primary endpoint (relative risk 1.59 95% confidence 
interval 1.02 - 2.47 for troponin elevation versus 1.16 95% confidence interval 
0.62-2.15 for increased creatine kinase). 
 
Conclusion: Increase of troponin T after elective percutaneous coronary 






Cardiac-specific troponins are useful in establishing diagnosis and predicting 
prognosis in patients with suspected acute coronary syndromes. In these 
patients, troponin has higher sensitivity and specificity compared to creatine 
kinase or its MB isoform (CK-MB) [1-4]. 
After elective percutaneous coronary intervention elevated cardiac enzymes can 
be observed even if the procedure is angiographically successful and 
uncomplicated. Elevations of CK-MB have been associated with an increased risk 
of repeat revascularisation, acute myocardial infarction and death (major adverse 
cardiac events, MACE) [5-8]. Despite the high sensitivity and specificity of 
troponin in acute coronary syndromes, there are conflicting results about the 
prognostic significance of increased troponin after elective percutaneous coronary 
intervention [9-24]. However, most studies report only a small number of patients 
[9-11,17-24]. Moreover, some studies include also patients with an acute 
coronary syndrome, which could have influenced the results [8,16,21]. 
To assess the incidence and predictive value of creatine kinase or troponin T 
elevation after elective percutaneous coronary intervention in daily practice, the 






It concerns a prospective, observational study [25]. The patient cohort included 
unselected patients who underwent elective percutaneous coronary intervention 
between June 2002 and August 2003 in the Isala klinieken, Zwolle, the 
Netherlands. All patients had symptomatic coronary artery disease with objective 
evidence of ischemia. Patients with percutaneous coronary intervention for ST 
elevation myocardial infarction were excluded, as well as patients with urgent 
percutaneous coronary intervention for acute coronary syndromes. 
 
Procedure and laboratory testing 
All angiographic and percutaneous coronary intervention procedures were 
performed according to the standard protocol. Routine care before and after the 
procedure was undertaken for all patients, including preprocedural use of aspirin 
and a bolus of intravenous heparin (5000 U) at the beginning of the procedure. All 
Troponin and CK after elective angioplasty 
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patients received a loading dose of 300 mg clopidogrel before the procedure, 
followed by 75 mg once daily for at least 28 days after the percutaneous coronary 
intervention. Use of glycoprotein IIb/IIIa receptor inhibitors or stents was left to the 
discretion of the interventional cardiologist. At the time the study was performed, 
the use of drug eluting stents was less than 10%. 
A blood sample was routinely obtained from all patients just before the 
interventional procedure in the catheterisation room. The second sample was 
taken 08.00 a.m. the day after, at least 12 and at maximum 22 hours after the 
procedure. All samples were prepared and stored locally in our core laboratory at 
-70°C until analysed. Troponin T was analysed using the third generation troponin 
T test (Roche diagnostics, Mannheim, Germany) with a threshold of 0.01 ng/ml. 
Although the 99th percentile of normal troponin T may be as low as 0.01 ng/ml, 
according to other recent studies we used 0.05 ng/ml as cut-off value [26-29]. 
Separate analyses were performed using 0.03 ng/ml as cut-off value. However, 
as we pre-specified a cut-off value of 0.05 ng/ml, the final analyses were 
performed with this cut-off value for troponin T. Rise of creatine kinase level 




Clinical outcomes were obtained at least 30 days after percutaneous coronary 
intervention by telephone interviews with the patient, their relatives or their 
cardiologist or primary physician. Using a standardised format, information about 
repeat coronary angiography, repeat revascularisation, myocardial infarction, 
cerebrovascular accident, re-admission because of angina and death was 
collected. All details about clinical events were also obtained from the medical 
files. 
Myocardial infarction during follow-up was defined as new onset of Q waves or 
creatine kinase and CK-MB elevation above cut-off values. All deaths during 
follow-up were considered of cardiac cause. 
 
Statistical analysis 
All analyses were performed with SPSS statistical software (SPSS Inc., Chicago, 
Illinois). Group comparisons were done by the chi-square test for proportions and 
Student t test for continuous variables. Primary endpoint was defined as the 
combined incidence of death, myocardial infarction, stroke, repeat angiography or 
re-admission because of anginal symptoms during the follow-up period. 
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To assess the potential association between increasing enzymes and increasing 
incidence of the primary endpoint, patients were categorised in three groups. 
Patients without increased enzymes consisted of the control group. Patients with 
increased enzymes were divided into two groups, using the median value of the 
whole group of patients with increased enzymes as the cut-off value between the 
second and third group, thereby creating an equal number of patients in the latter 
2 groups (TnT 0.13 ng/ml, CK 250 IU/L). 
Multivariate analyses (logistic regression analyses) were performed to assess the 
independent association between increased troponin T or creatine kinase after 
the procedure and the occurrence of cardiac events in follow-up. A value of p < 





During enrolment, 745 patients were screened for our study. Of these 745 
patients, a total of 713 patients (96%) had no elevated troponin T (<0.05 ng/ml) 
before the percutaneous coronary intervention, representing the final study group. 
Mean age was 64 years (SD 10.3), 211 patients (30%) were female and 127 
patients (18%) had diabetes. Multivessel disease was present in 344 patients 
(48%) and 111 patients (16 %) had angina with CCS class 4. A total of 501 
patients (70%) were treated with a stent and 146 patients (20%) had angioplasty 
of more than 1 vessel. Percutaneous coronary intervention of a bypass graft was 
performed in 25 patients (4%). 54 patients (8%) received glycoprotein IIb/IIIa 
receptor inhibitors. Increased troponin T (>0.05 ng/ml) after the procedure was 
documented in 150 patients (21%) (mean in this group 0.29 ng/ml, SD 0.51; 
range 0.051-3.98) and increased creatine kinase in 66 patients (9%) (mean 
creatine kinase in this group 325 IU/L, SD 217; range 180-1187). Furthermore, 
684 patients (96%) had preprocedural and 463 patients (65%) had postprocedural 
undetectable levels of troponin T (<0.01 ng/ml). 
Baseline variables according to elevated troponin T (>0.05 ng/ml) after the 
percutaneous coronary intervention are shown in table 1. Patients with troponin T 
elevation more often had creatine kinase elevations (32%) compared to those 
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Table 1. Baseline characteristics of 713 pts after elective PCI without increased troponin 
(<0.05 ng/ml) before the PCI according to increased troponin (>0.05 ng/ml) after the PCI. 
 








  P 
    
Age, yrs 63.5 (±10) 63.7 (±11) 0.84 































Percutaneous coronary intervention             









































Mean or number (sd or %) 
 
 
Table 2 shows baseline variables according to increased creatine kinase after the 
percutaneous coronary intervention. After multivessel percutaneous coronary 
intervention there was a significant increase of both troponin T and creatine 
kinase. Only 11 patients (1.5 %) had after the PCI suboptimal blood flow, defined 
as Thrombolysis In Myocardial Infarction (TIMI) flow less than 3. Of these 
patients, 3 had elevated troponin T and CK after the procedure (NS). Accordingly, 
observed TIMI flow after the PCI could not explain the majority of increased TnT 
or CK. 
 
Mean follow-up was 10.9 months (SD 10.6), and 30-day follow-up was available 
in all patients. The primary endpoint was documented in 139 patients (19.5%) and 
was significantly observed more often in patients with diabetes, multivessel 
disease or multivessel percutaneous coronary intervention. Also patients with a 
previous revascularisation by either percutaneous coronary intervention or 
coronary artery bypass grafting had a higher incidence of the primary endpoint. 
Differences between patients with and without elevated cardiac enzymes with 




Table 2. Baseline characteristics of 713 pts after elective PCI without increased troponin 
(<0.05 ng/ml) before the PCI according to increased creatine kinase (>180 IU/L with CK-MB 
>4%) after the PCI. 
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Percutaneous coronary intervention 














































Table 3. Events during follow-up of 713 pts after elective PCI without increased troponin 
(<0.05 ng/ml) before the PCI according to increased troponin (>0.05 ng/ml) and increased 
creatine kinase (>180 IU/L) after the PCI. 
 

















  P 
       
Death 9 (1.6) 0 0.12 9 (1.4) 0 0.34 
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Mortality was low and neither associated with elevated troponin T nor creatine 
kinase. There was, however, a strong association between the occurrence of 
myocardial infarction and postprocedural increase of both troponin T and creatine 
kinase. Increased troponin T was also associated with re-admission for anginal 
complaints. Increased troponin T but not increased creatine kinase was 
associated with increased incidence of the primary endpoint. There was also an 
association between increasing troponin T after the percutaneous coronary 
intervention and increasing incidence of the primary endpoint (figure 1, panel A). 
There was no association between categories of increased creatine kinase and 
the primary endpoint (figure 1, panel B). 
 
 
To assess the independent association between increased troponin T or creatine 
kinase and the primary endpoint, multivariable analyses were performed. The 
unadjusted odds ratio of increased creatine kinase was 1.24 (95% CI 0.68-2.28). 
After adjusting for differences in age, gender, multivessel percutaneous coronary 
intervention, diabetes and angina class, the odds ratio of increased creatine 
kinase for the incidence of the primary endpoint was 1.16 (95% CI 0.62-2.15). 
The unadjusted odds ratio of increased troponin T was 1.55 (95% CI 1.01-2.38). 
After multivariable analyses, the odds ratio of increased troponin T for the 
incidence of the primary endpoint was 1.59 (95% CI 1.02-2.47). 
Using 0.03 ng/ml as cut-off value for troponin T elevation, patients with increased 
troponin T after the procedure had the combined endpoint in 26.6% compared to 
















Figure 1. Association between categories of troponin T (panel A) or creatine kinase (panel 
B) and the incidence of the combined clinical endpoint after elective percutaneous coronary 
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P = 0.77 
Creatine kinase level (IU/L) after elective PCI 
 




The present study shows an association between troponin T rise after elective 
percutaneous coronary intervention and cardiac events during follow-up. Mortality 
in this low-risk population was low, and was neither associated with troponin T nor 
creatine kinase increase. Increased creatine kinase was only significantly 
associated with myocardial infarction during follow-up. In patients with elective 
percutaneous coronary intervention, the prognostic value of troponin T is more 
important than creatine kinase. 
 
Mechanism 
There may be several explanations for the worse prognosis of patients with 
enzyme increase after elective percutaneous coronary intervention. It has been 
demonstrated that troponin increase after percutaneous coronary intervention 
was associated with more complex procedures, with prolonged inflation times, 
complex lesion morphology [17] and more often side branch occlusion [31]. Also, 
patients with troponin elevation may have an increased systemic inflammatory 
state [32]. Magnetic resonance imaging studies showed that even small increases 
of cardiac markers (either CK-MB or Troponin I) after percutaneous coronary 
intervention are associated with new irreversible myocardial injury [33,34]. The 
adverse consequences of myocardial damage caused by percutaneous 
interventions may be similar to spontaneous myocardial damage [7]. Another 




In comparison with other studies with a similar follow-up period, the event rate in 
our study was low. The average long-term incidence of the combined endpoint of 
death, myocardial infarction or recurrent revascularisation in four other 
comparable studies was 19.1%, compared to 12.8% in our study [10,12,20,23]. 
Mortality in our patient cohort was 1.3 % compared to 3.8% in the four previous 
studies. Cavallini et al, recently showed a linear association between 2-years 
mortality and CK-MB elevation, but did not find such relation between troponin I 
elevation and death [8]. However, more than half of their patients had an acute 
coronary syndrome, with a direct effect on prognosis, probably influencing the 
results. A small study of 269 patients undergoing elective stent implantation 
showed a significant association between postprocedural troponin T and the 
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combined endpoint of death, myocardial infarction and coronary bypass grafting 
during follow-up [9], which was confirmed by three other small studies focusing on 
MACE [10,11,19]. Another study however, could not confirm this relation in 1129 
patients during 8-months follow-up [12]. In a meta-analysis of 7 small studies, 
there was a significant association between troponins (I and T) and the combined 
endpoint of myocardial infarction/death, but not between increased troponin and 
MACE [13]. Two other studies could not demonstrate an association between 
postprocedural troponin I rise and mortality in 1-year follow-up [14,15]. In patients 
with chronic renal failure, but not on dialysis, postprocedural troponin I rise seems 
to be strongly associated with mortality as well as with MACE in follow-up [20]. 
 
Study limitations 
Our study has several limitations. First, the number of patients was relatively 
small and the follow-up period relatively short. However, most previous studies 
had an even smaller sample size and also a short follow-up period. Second, the 
primary combined endpoint included five different endpoints. However, a study in 
such a low-risk population with only endpoint death or myocardial infarction 
should include thousands of patients to be powered. Third, there was no detailed 
description of lesion morphology and angiographic complications of the 
percutaneous coronary intervention such as side branch occlusion. Fourth, the 
use of glycoprotein IIb/IIIa receptor inhibitors was low, as could be expected in 
this low risk population [36]. Fifth, although our study is a prospective, non-
randomised registry, there was no routine angiographic follow-up. Sixth, although 
the used cut-off value of 0.05 ng/ml for troponin T is commonly used, cut-off 
values of 0.01 and 0.03 ng/ml might be used as well [37,38]. However, additional 
analyses with 0.03 ng/ml as cut-off value did not change the conclusions, and, as 
mentioned earlier, 0.05 ng/ml was pre-specified in the protocol and therefore used 
in the final analysis. Finally, the blood samples after percutaneous coronary 




The recently revised European guidelines for percutaneous coronary intervention 
do not recommend the use of troponin T after percutaneous coronary intervention 
[39]. However, the recommendation in these guidelines seems to be based on 
only four studies, including one meta-analysis which included studies that were 
not yet published [13]. According to the also recently revised ACC/AHA 
Troponin and CK after elective angioplasty 
32 
guidelines, most patients can be safely discharged within 24 h after an elective, 
uncomplicated percutaneous coronary intervention [40]. Biochemical evidence of 
periprocedural myocardial infarction is defined by rise of CK-MB or troponin I or T 
after percutaneous coronary intervention. Determining these markers is 
recommended for patients with signs or symptoms suggestive of myocardial 
infarction or angiographic evidence of complications, although routine 
measurement of these cardiac biomarkers seems to be reasonable 8 to 12 hours 
after the procedure, according to these American guidelines. 
Our study suggests that troponin T is better to identify patients at risk for future 
cardiac adverse events when compared to creatine kinase. 
 
Conclusion 
Troponin T predicts better than creatine kinase future cardiac events in patients 
undergoing elective percutaneous coronary intervention. Whether more intensive 
monitoring and treatment of patients with increased troponin T after percutaneous 
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Background: Elevated troponin after elective percutaneous coronary intervention 
(PCI) has been associated with a worse prognosis. Pre-treatment with clopidogrel 
may be beneficial in patients undergoing PCI. Therefore, a prospective 
observational study was conducted to address the potential role of clopidogrel in 
reducing troponin release after elective PCI. 
 
Methods: Troponin T was measured 12 hours after elective PCI in 656 patients 
without elevated troponin before PCI. To assess the independent association 
between pre-treatment with clopidogrel and increased troponin, multivariate 
analyses were performed. 
 
Results: Mean age of the 656 patients was 63.5 years (SD 10.2), 194 patients 
(30%) were female and 114 patients (17.4%) had diabetes. In 217 patients (33%) 
troponin was increased after PCI. Of the 330 patients who were not pre-treated 
with clopidogrel, 118 patients (34%) had increased troponin after the PCI 
compared to 99 patients (30%) of the 326 patients who were treated with 
clopidogrel longer than 24 hours before the procedure (p=0.14). Stratified 
analyses showed that patients with older age (p=0.03), previous PCI (p=0.013), 
angina CCS 4 (p=0.03) and multivessel disease (p=0.04) had a significantly lower 
risk of troponin increase after pre-treatment with clopidogrel compared to patients 
without pre-treatment. After adjusting for differences in the other variables, 
patients who were pre-treated with clopidogrel had a significant lower risk of post-
PCI increase of troponin T (odds ratio 0.69, 95% confidence interval 0.49-0.99). 
 
Conclusion: Pre-treatment with clopidogrel is associated with a significantly 
lower incidence of increased troponin after elective PCI. Combined with results of 





Intensive antiplatelet therapy is the cornerstone of pharmacological treatment of 
patients undergoing percutaneous coronary intervention (PCI) and may consist of 
aspirin, GP IIb/IIIa inhibitors and the ADP antagonist clopidogrel [1-3]. In addition 
to postprocedural treatment with clopidogrel, treatment with clopidogrel before 
PCI may also be beneficial [4-8], although a small study could not confirm this 
observation [9]. However, these data are based on selected patients included in 
randomised clinical trials, and the results may be not comparable to these 
observed in daily practice. 
Postprocedural rise of troponin levels has been associated with an increased 
incidence of cardiac events during follow-up [10,11]. Troponin release occurs in 
approximately 30% of patients and has been related to complications during the 
procedure, including sapheneous vein graft interventions, multistent use, 
glycoprotein IIb/IIIa use, and a history of hypercholesterolemia [12].  
We studied the potential association between pre-treatment with clopidogrel on 
the postprocedural troponin levels in consecutive, unselected patients undergoing 






A prospective, observational study was performed. The patient cohort included 
unselected patients who underwent elective PCI between June 2002 and August 
2003 in a single centre (Isala klinieken, Zwolle, the Netherlands). All patients had 
symptomatic coronary artery disease with objective signs of ischemia. 
Patients with PCI for ST-segment elevation MI were excluded, as well as patients 
with urgent PCI for severe unstable coronary artery disease. The remaining 
patients consisted of outpatients with stable angina and patients referred from 
other hospitals with more severe or progressive angina. At the time when the 
study was performed, routine use of clopidogrel before PCI was not advised, 
leaving it at the discretion of the referring treating cardiologist. Use of clopidogrel 
before PCI was defined as starting clopidogrel more than 24 hours before PCI. All 
patients who were not treated with clopidogrel before the PCI received a loading 
dose of 300 mg clopidogrel just before the procedure. All patients were treated 
with clopidogrel 75 mg once daily for at least 28 days after the procedure. 
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Procedure and laboratory testing 
Routine care before and after the procedure was undertaken for all patients, 
including the preprocedural use of aspirin and a bolus of intravenous heparin 
(5000 U) at the beginning of the procedure. Use of stents or GP IIb-IIIa inhibitors 
was left at the discretion of the interventional cardiologist. 
A blood sample was routinely obtained from all patients just before the 
interventional procedure in the catheterisation room. The second sample was 
taken the day after, 12-16 hours after the procedure. All samples were prepared 
and stored locally in our core laboratory at -70°C until analysis. 
Troponin T was analysed using the third generation troponin T test (Roche 
diagnostics, Mannheim, Germany) with a threshold of 0.01 ng/ml, which was used 
in our study as the cut-off value. 
 
Statistical analysis 
Differences in baseline characteristics between patients with and without 
clopidogrel pre-treatment and those with and without increased troponin after the 
PCI procedure were compared by means of the Chi-square test or Fisher’s exact 
test for proportions and Student’s t test for continuous variables. 
Multivariate analysis (logistic regression analysis) was performed to assess the 
independent association between pre-treatment with clopidogrel and increased 
troponin level after the procedure. A two-tailed p value of <0.05 was considered 
statistically significant. All analyses were performed with SPSS statistical software 





Of 745 patients enrolled in the study, data on treatment with clopidogrel before 
admission was available in 714 patients (96%). Of these 714 patients, a total of 
656 patients (92%) had no elevated troponin T (<0.01 ng/ml) before the PCI and 
these patients represent the final study group. Mean age was 63.5 years (SD 
10.2), 194 patients (30%) were female and 114 patients (17.4%) had diabetes. 
Multivessel disease was present in 314 patients (48%), and 101 patients (15%) 





In a total of 326 patients (50%), clopidogrel was started 24 hours or more before 
PCI. Differences between patients with and without pre-treatment with clopidogrel 
are summarised in table 1. Patients who were pre-treated with clopidogrel were 
younger, were more often waiting in a referring hospital for the PCI and had less 
often diabetes or a history of PCI. Patients with angina class 4 more often had 
clopidogrel started 24 hours or more before the PCI. 
 
 
Table 1. Baseline clinical and target lesion characteristics of 656 patients with elective PCI, 











  P 
    
Age, yrs (sd) 62.6 (±10.6) 64.4 (±9.7) 0.02 
Female 105 (32) 89 (27) 0.14 
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All in n (%), except when is indicated else    
 
 
In 217 patients (33%), troponin was increased after the PCI. Differences between 
patients with and without increased troponin after the PCI are shown in table 2. 
Patients with increased troponin more often had multivessel disease, all other 
variables were not significantly different. Of the 330 patients who were not pre-
treated with clopidogrel, 118 patients (34%) had increased troponin after the PCI 
compared to 99 patients (30%) of the 326 patients who were treated longer than 
24 hours before the PCI with clopidogrel (p=0.14). During hospital admission, 
there were no patients with intracerebral hemorrhage or signs of stroke. 
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Table 2. Predictors of increased troponin (>0.01 ng/ml) after elective PCI in 656 patients 
without increased troponin (<0.01ng/ml) before the PCI and with data on clopidogrel use. 
 








  P 
    
Age, yrs (sd) 63.0 (±9.9) 64.3 (±10.7) 0.13 













































































All in n (%), except when is indicated else    
 
 
A stratified analysis was performed to assess whether specific subgroups had 
more benefit of pre-treatment with clopidogrel (Figure 1). There was a consistent 
reduction of the risk of troponin elevation after PCI after pre-treatment with 
clopidogrel in all subgroups. It was demonstrated that particularly patients at older 
age (p=0.03), with previous PCI (p=0.013), with angina CCS 4 (p=0.03) and 
multivessel disease (p=0.04) had a significantly lower risk of troponin increase 






Figure 1. Stratified analyses of risk of increased troponin after pre-treatment with 
clopidogrel in several subgroups (no pre-treatment is the reference group). 
Hazard ratio (95% CI) for troponin-increase 
after clopidogrel pre-treatment 
0 1 0.5 1.5 2 
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Since there were several significant differences between patients with and without 
pre-treatment with clopidogrel, multivariate analysis was performed to assess the 
independent association between pre-treatment with clopidogrel and troponin 
increase after the PCI. The results of multivariate analyses are presented in table 
3. After adjusting for differences in the other variables, patients who were pre-
treated with clopidogrel had a significant lower risk of post-PCI increase of 
troponin T (odds ratio 0.69, 95% confidence interval 0.49-0.99; p=0.04). 
 
 
Table 3. Predictors of increased troponin (>0.01 ng/ml) after elective PCI in 656 patients 




Variable       Odds ratio  95% Confidence Interval   P 
 
Age (/year)    1.01   0.99-1.03  0.30 
Male gender   0.96   0.66-1.41  0.85 
Diabetes   0.89   0.56-1.41  0.62 
Previous PCI   0.67   0.44-1.0  0.05 
Angina CCS 4   1.37   0.85-2.2  0.20 
Smoking   1.15   0.78-1.70  0.48 
Multivessel disease   1.46   1.0-2.1   0.04 
PCI of LAD   1.24   0.87-1.76  0.24 
Multivessel PCI   2.07   1.37-3.15  0.001 






Our study shows that in patients undergoing elective PCI, pre-treatment with 
clopidogrel was associated with a decreased risk of elevated troponin after the 
PCI. Several subgroups, including older age and those with multivessel disease, 
CCS class 4 angina or previous PCI had particular benefit of pre-treatment with 
clopidogrel. 
The results of our study are consistent with observations from randomised trials. 
In the TARGET study, 4809 patients undergoing elective or urgent PCI were 
randomised to tirofiban or abciximab. A sub-analysis of patients with clopidogrel 
pre-treatment showed a lower incidence of cardiovascular events at 30 days and 
a lower mortality at 1 year [4]. The beneficial effect of pre-treatment with 
clopidogrel was also suggested in the PCI-CURE study, involving patients with an 
acute coronary syndrome without ST-segment elevation [5]. Furthermore, 
Berglund et al found a significant beneficial effect of clopidogrel pre-treatment in 
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reducing myocardial infarction and percutaneous reintervention after PCI. 
However, this concerned a non-randomised study in patients with unstable 
coronary syndromes [6]. 
The Clopidogrel for the Reduction of Events During Observation (CREDO) study, 
including 2116 patients, has shown that pre-treatment with clopidogrel has no 
beneficial effects. However, when subgroup analysis was performed with regard 
to duration of pre-treatment, its seemed that a longer duration of pre-treatment 
(>6 hours) is beneficial [7]. In ISAR-REACT there was no difference in the 30 
days outcome between those pre-treated with clopidogrel 2-3 hours versus >12 
hours. However, this trial had many exclusion criteria, resulting in inclusion of a 
very low risk population [8]. In another small study in 203 patients undergoing 
elective stent implantation, clopidogrel pre-treatment of 3 days did reduce neither 
the post-procedural release of troponin I and CK-MB nor cardiovascular events 
during 6 months follow-up [9].  
Several studies have been conducted to address platelet aggregation inhibition 
and the timing of clopidogrel administration. It has been shown that a 300 mg 
clopidogrel loading dose, given 3 to 24 hours before stenting, is associated with a 
better platelets inhibition and a reduced poststent activity, when compared to a 75 
mg dose given at the time of the procedure [13]. In a non-randomized, 
observational study, the effects of a 600 mg loading dose of clopidogrel at 
different time periods before elective PCI were studied [14]. After 2 hours, the 
level of platelet aggregation and the surface expression of P-selectin and 
activated glycoprotein IIb/IIIa did not further change with time after clopidogrel 
administration. Furthermore, they could not demonstrate any difference in clinical 
endpoints at 30 days. The large inter-individual variability in the platelet inhibitory 
response from clopidogrel [15] and the inclusion of low-risk patients, in small 
studies, may possibly explain the failure to show significant differences between 
achieved platelet aggregation in patients with or without pre-treatment with 
clopidogrel [16,17]. 
Apart from direct effects on platelet aggregation, clopidogrel may also have 
effects on the inflammatory response. It has been demonstrated that clopidogrel 
pre-treatment (longer than 24 hours before PCI) reduces platelet inflammatory 
marker expression in patients undergoing PCI compared to patients without pre-
treatment [18]. Although a high loading dose of 600 mg clopidogrel may optimise 
platelet inhibitory effects early after intervention and may provide a more effective 
protection against early thrombotic complications [14,19], the question remains 
Pre-treatment with clopidogrel 
46 
whether this has comparable effect on the inflammatory response. Therefore, 
further research on this topic might be necessary. 
 
Our study confirms earlier reports that a relatively high number of patients with 
elective PCI develop elevated troponin, even if the procedure is successful and 
uncomplicated. These elevations, even when minor, have been associated with 
an increased incidence of repeat revascularisations, acute myocardial infarction 
and death [10,20-23]. 
 
Limitations 
Our study has several limitations. We present data from a prospective, 
observational study, without randomisation. Because pre-treatment with 
clopidogrel was left to the discretion of the cardiologist, the decision for pre-
treatment may have introduced confounding. Probably, patients who were pre-
treated with clopidogrel may represent a more unstable group. It is therefore not 
surprising that significant differences could be observed between patients with 
and without pre-treatment with clopidogrel (table 1). Nevertheless, after correction 
for these confounding variables, a significantly lower risk of post PCI troponin rise 
was demonstrated in patients pre-treated with clopidogrel. We did not perform a 
sample size calculation. Because the sample size of the study was not very large, 
the number of patients in the subgroups were small. The study was not designed 
and powered to assess potential association between clopidogrel pre-treatment, 
troponin release and outcome. With our sample size and a low-risk population, a 
significant difference in events during follow-up can not be expected. Another 
limitation is that we had neither data on levels of platelet aggregation inhibition 
nor data on angiographic causes of troponin elevation, including loss of side 
branches, distal embolization or no-reflow. Also, we didn’t collect data on bleeding 
complications (although there were no patients with intracerebral hemorrhage). 
 
Conclusion 
Clopidogrel pre-treatment before elective PCI is associated with a decreased risk 
of post-PCI troponin rise. Combined with results of several randomised trials, pre-
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Background: Although techniques of percutaneous coronary interventions (PCI) 
have improved, patients with PCI of more vessels may still have an increased 
risk. We performed a prospective observational study evaluating the differences 
between multivessel and single-vessel procedures according to postprocedural 
troponin T (TnT) elevation and events during follow-up. 
 
Methods: The study included 713 patients without elevated TnT (<0.05 ng/ml) 
before PCI. Primary endpoint was the combined endpoint of death, myocardial 
infarction, stroke, repeat coronary angiography and re-admission for anginal 
symptoms during the mean follow-up of 10.9 months. 
 
Results: TnT after PCI was elevated in 150 patients (21%) and was significantly 
associated with an increased incidence of the primary endpoint (RR 1.55 95% CI 
1.01-2.38). PCI of more than one vessel was performed in 146 patients (20%). 
These patients more often had increased TnT levels after the procedure (31.5% 
vs 18.3%, p=0.001) and an increased incidence of the primary endpoint during 
follow-up (28% vs 19%, p=0.01). After multivariable analysis, multivessel PCI was 
a statistically significant predictor of postprocedural TnT increase (OR 1.90, 95% 
CI 1.17-3.06). Multivessel PCI was also associated with an increased risk of the 
primary endpoint (OR 1.73, 95% CI 1.18-2.52), but after adjusting for multivessel 
disease this association was not statistically significant (OR 1.42, 95% CI 0.92-
2.19). 
 
Conclusion: Elective PCI of more vessels in one session is, in comparison with 
single-vessel PCI, more often associated with postprocedural troponin T rise and 
a (non-significantly) higher incidence of cardiac events during follow-up. Whether 





During the last decade, percutaneous coronary intervention (PCI) has been 
improved [1]. Use of (drug eluting) stents has decreased the occurrence of re-
stenosis. Furthermore, PCI is now often combined with diagnostic coronary 
angiography in one procedure [2,3]. Another development is performing 
multivessel PCI in one session. Although it was not confirmed by a recently 
published registry [4], randomised trials suggested that in most patients with 
multivessel disease, PCI is comparable to coronary artery bypass grafting 
(CABG) according to mortality and myocardial infarction (MI) in follow-up [5]. 
Performing more interventions in one procedure may be faster and more 
convenient than staged procedures. Although one study suggests that this one-
session strategy might be more harmful, there are only few data on this issue [6]. 
After elective PCI, up to 30% of patients develop elevated cardiac specific 
troponin T (TnT) even when the procedure is considered successful and 
uncomplicated. Such elevations of TnT have been associated with an increased 
incidence of future cardiac events [7-11]. 
The current prospective study was designed to evaluate the effect of multivessel 
PCI versus single vessel PCI on the incidence of troponin T (TnT) elevation after 
elective PCI and the occurrence of cardiac events during follow-up. 
 
 
Materials and Methods 
 
Study population 
It concerns a prospective, observational study [11]. The patient cohort included 
unselected patients who underwent elective PCI between June 2002 and August 
2003 in Isala klinieken, Zwolle, the Netherlands. All patients had symptomatic 
coronary artery disease with objective evidence of ischemia. 
Patients with single vessel as well as patients with multivessel disease were 
included. Multivessel disease was defined as more than 50% stenosis in two or 
more major coronary arteries. If in patients with multivessel disease, culprit lesion 
interventions only or multivessel interventions for multiple lesions in more than 
one vessel were indicated, depended of the decision of the cardiologist and 
cardiac surgeon (heart team). Patients with acute coronary syndrome (ACS) were 
excluded. 
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Procedure and laboratory testing 
All PCI procedures were performed according to the standard protocol. Routine 
care before and after the procedure was undertaken for all patients, including 
preprocedural use of aspirin and a bolus of intravenous heparin (5000 U) at the 
beginning of the procedure. Patients not on clopidogrel (approximately 50%) 
received a loading dose of 300 mg clopidogrel just before the procedure. 
Postprocedure, all patients were treated with clopidogrel 75 mg once daily for at 
least 28 days. Use of GP IIb-IIIa inhibitors or stents was at the discretion of the 
interventional cardiologist. At the time the study was performed, the use of drug 
eluting stents was less than 10%.  
A blood sample was routinely obtained from all patients just before the 
interventional procedure in the catheterisation room. The second sample was 
taken the day after, approximately 12 hours after the procedure. All samples were 
prepared and stored locally in our core laboratory at -70°C until analysed. The 
medical practitioners were blinded for the results of this analysis. 
TnT was analyzed using the third generation troponin T test (Roche diagnostics, 
Mannheim, Germany) with a threshold of 0.01 ng/ml. Although the 99st percentile 
of normal TnT may be as low as 0.01 ng/ml, in accordance with other recent 
studies we used 0.05 ng/ml as cut off value [12-14]. 
 
Endpoints 
The primary endpoint was the combined incidence of re-admission because of 
angina, repeat coronary angiography, repeat revascularisation, MI, stroke and 
death. The second primary endpoint was TnT elevation after PCI. Clinical 
outcomes were obtained at least 30 days after PCI by telephone interviews with 
the patient, their relatives or eventually their cardiologist or primary physician. 
Information on clinical events was noted using a standardised format. All clinical 
events were obtained from the medical files. New onset of Q waves or CK and 
CK-MB above cut off values was used as definition for MI during follow-up. All 
deaths during follow-up were considered of cardiac cause, unless a noncardiac 
cause was identified. 
 
Statistical analysis 
All analyses were performed with SPSS statistical software (SPSS Inc., Chicago, 
Illinois). Group comparisons were done by the chi-square test for proportions and 
Student t test for continuous variables. Multivariable analysis by logistic 
regression were performed to asses the independent association between 
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multivessel PCI and increased TnT after the PCI. Multivariate Cox’ proportional-
hazards regression analysis was applied to describe the independent relation 
between multivessel PCI and the occurrence of the primary endpoint during 





During the enrolment period, 745 patients were screened for our study. Of these 
745 patients, a total of 713 patients (96%) had no elevated TnT (<0.05 ng/ml) 
before the PCI, representing the final study group. Mean age was 64 years (range 
35-87 years), 211 patients (30%) were female, 127 patients (18%) had diabetes 
and 111 patients (16%) had angina with CCS class 4. A total of 501 patients 
(70%) were treated with a stent. Multivessel disease was present in 381 patients 
(53%) which was documented before the PCI procedure in 344 patients (90%). 
PCI of more than one vessel was performed in 146 patients (20%). Differences 
between patients with multivessel PCI and PCI of one vessel are summarized in 




Table 1. Characteristics of 713 pts; multivessel procedure versus single-vessel procedure. 





  P 
    
Age, yrs (sd) 64.1 (±10.3) 63.4 (±10.4) 0.46 






Family history of CAD 


























































All in n (%), except when is indicated else 
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Baseline characteristics of the 381 patients in the subgroup with multivessel 
disease did not differ essentially from the entire study group of 713 patients. 
There were only few differences between patients undergoing multivessel and 
single vessel PCI in this subgroup. Patients with previous CABG less often had 
multivessel PCI (8% vs 24%, p <0.001), whereas previous PCI (31% vs 26%) and 
MI in history (50% vs 49%) were not significantly different. Furthermore, patients 
with PCI of the right coronary artery significantly more often had multivessel PCI 
(37% vs 26%, p =0.03). 
In patients with multivessel disease, postprocedural troponin elevation occurred 
significantly more often in patients undergoing multivessel PCI compared to single 
vessel PCI (32% vs 20%, p =0.008). However, multivessel PCI was neither 
significantly associated with mortality in follow-up, nor with the primary combined 
clinical endpoint in this selected group (27% vs 21%, p =0.19). 
 
 
Table 2. Baseline characteristics of 713 pts according to troponin increase (>0.05 ng/ml) 
after elective PCI. 
 





  P 
    
Age, yrs (sd) 63.5 (±10) 63.7 (±11) 0.84 














































































TnT was elevated after the PCI in 150 patients of the total study population 
(21%). All baseline variables according to elevated troponin after the PCI are 
shown in table 2. Multivessel disease and multivessel PCI were both significantly 
associated with increased TnT rise after PCI (p=0.001). The unadjusted odds 
ratio (OR) for increased TnT after multivessel PCI was 2.1 (95% CI 1.4-3.1). After 
multivariable analyses, adjusting for age, gender, diabetes, CCS classification 
and multivessel disease, multivessel PCI (OR 1.9, 95% CI 1.17-3.06), but not 
multivessel disease (OR 1.17, 95% CI 0.76-1.8) was significantly associated with 
increased TnT after the PCI. 
 
30-days follow-up was available in all patients, mean total follow-up was 10.9 
months (SD 10.6). Long-term mortality was low (1.3%) and associated with 
neither multivessel PCI nor TnT elevation after PCI. The occurrence of the 
combined endpoint death and/or MI in follow-up was also low and not related to 
troponin release (2.1% (12/563) for patients with non-elevated troponin vs 4.0% 
(6/150) for patients with elevated troponin, NS). Patients with multivessel PCI had 
more often recurrent PCI (19 patients, 13.0%) compared to single vessel PCI (39 
patients, 6.9%, p =0.016). 
During the follow-up period, the primary combined endpoint was observed in 139 
patients (19.5 %): 9 patients died (2 of noncardiac, 7 of cardiac or unknown 
cause), 8 patients had a MI and 64 underwent recurrent revascularisation (49 
PCI, 6 CABG, 9 PCI and CABG). Furthermore, 7 patients had a stroke, 36 
patients underwent re-angiography and another 15 patients were re-admitted for 
anginal symptoms. 
 
Differences between patients with and without a primary endpoint during the 
follow-up period are shown in table 3. An increased risk of occurrence of the 
primary endpoint was observed in patients with diabetes, in patients with a PCI or 
CABG in history, in patients with multivessel disease and in patients with an 
increased TnT after PCI. Also patients with PCI of more vessels had significantly 
more events during follow-up, with the unadjusted odds ratio 1.7 (95% CI 1.2-2.5). 
After adjusting for differences in age, gender, diabetes and CCS classification, 
multivessel PCI had an increased incidence of the primary endpoint, OR 1.73, 
95% CI 1.18-2.52. However, if multivessel disease was also included in the 
multivariable model, the association was not statistically significant, OR 1.42 
(95% CI 0.92-2.19). 
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Table 3. Baseline characteristics of 713 pts according to cardiac events1 during follow-up. 
 
Variables Patients with events  
(n=139) 
Patients without events     
(n=574) 
 
  P 
    
Age, yrs (sd) 64.9 (±10.3) 64.9 (±10.3) 0.8 
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Multivessel PCI was, in comparison with single vessel procedure, significantly 
associated with more often postprocedural TnT release. Multivessel PCI was also 
associated with an increased incidence of cardiac events during the follow-up 
period, but this could in part be explained by multivessel disease itself. Mortality in 
this low-risk population was low and not associated with multivessel PCI. 
 
In patients undergoing elective multivessel PCI, there are conflicting results about 
the safety and long term results. One study reported similar clinical outcomes for 
patients undergoing multivessel PCI when compared with patients undergoing 
single vessel PCI [15]. Others report comparable events in follow-up for both 
groups, except for re-PCI, occurring more frequent in patients undergoing 
multivessel PCI [16,17]. IJsselmuiden et al randomized 219 patients with 
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multivessel disease to complete versus culprit vessel PCI, resulting in similar 
major adverse cardiac events at follow-up and similar total costs after one year in 
the two groups [18]. Recently, it was observed that in patients planned for 
multivessel PCI, interventions of hemodynamically non-significant stenoses can 
be safely deferred, based on fractional flow reserve (FFR) measurements [19]. 
 
In an analysis of the TARGET study, multivessel PCI was, when compared with 
single vessel PCI, more often associated with events in follow-up, primarily due to 
an increase in periprocedural MI [20]. However, one important, but not reported 
baseline characteristic was the presence of multivessel disease, which might 
have influenced the results. Other studies reported a relation between 
periprocedural myocardial injury and multivessel PCI [21,22]. Only one study 
compared staging of multivessel PCI with the one-procedure approach [6], with a 
non-significant trend that patients in the staged group had less cardiac events 
(p=0.08). This trend was mainly the result of a lower need for reinterventions. In 
the setting of ST-elevation MI, it is yet unknown whether treatment of only the 
infarct-related-artery is superior to multivessel intervention [23,24]. 
 
Troponin release after PCI occurs in approximately 30% of patients and has been 
related to several patient-related factors, including multivessel coronary artery 
disease, older age, interventions of de-novo lesions, sapheneous vein graft 
interventions and complex lesions [22]. Also procedure-related factors may be of 
importance, like the no-reflow phenomenon, distal embolization and side branch 
occlusion [25]. 
 
Since troponin release is associated with several procedure-related factors, it is 
not surprising that performing PCI in more than one vessel during the same 
procedure is (also in our study) associated with more often troponin release after 
PCI. This can be explained by several mechanisms: First, it has been 
demonstrated that postprocedural enzyme release relates to intraprocedural 
reduction of plaque volume, pointing towards the significance of 
atheroembolization in peri-procedural myocardial injury [26]. Therefore, PCI of 
more vessels, reducing more plaque volume, may result in more often significant 
enzyme release. Second, in vivo plaque disruption by PCI causes shedding of 
potent biofactors such as tissue factor into the coronary circulation, leading to 
microvascular thrombosis and no-reflow [27]. This thrombogenic state can 
influence the result of additional PCI procedures in the same setting. Third, as 
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PCI directly result in activation of the sympathetic nervous system, which in turn 
result in diffuse vasoconstriction [28], every additional PCI performed can result in 
extra troponin release. 
 
Staging of the PCI by performing first a single vessel procedure, followed weeks 
or months later by an additional procedure might result in less troponin release 
and less cardiac events, although this has not been proven yet. More often use of 
FFR may prevent unnecessary PCI. 
 
Limitations 
The presented study has some limitations. First, it concerns an observational 
study and differences between patients with and without multivessel disease 
could have influenced the results. Second, because mortality and MI in this group 
are low, the primary combined endpoint consisted of a number of different 
endpoints. These endpoints may be considered as weak, but an important reason 
for performing elective PCI is to improve quality of life. Knowing the low risk of 
events after elective PCI in stable patients and realising re-admission and repeat 
angiography are “events” in the patients point of view, these two endpoints were 
also included in the primary combined endpoint. Third, the number of patients 
was relatively small. Together with the low mortality during follow-up, no 
association could be demonstrated between multivessel PCI, TnT release and 
mortality, although it is not excluded that this relation does exist. As a 
consequence of the relatively low number of patients and particularly the low 
event rate, additional subgroup analyses, for example stratifying to the magnitude 
of troponin release, were not possible. Fourth, the use of drug eluting stents was 
low. Although this probably will not have influenced data on troponin release, it 
might have influenced the follow-up data, especially the need for recurrent 
revascularization. Fifth, approximately 50% of our patients were not on 
clopidogrel before the PCI and received the drug just before the procedure. This 
could have influenced the results, because the protective effect of clopidogrel is 
stronger when it is given several hours or more before the procedure [29]. Sixth, 
no routine angiographic follow-up was available for our patient cohort. Finally, as 
a routine electrocardiogram was not collected in the follow-up period, the number 







A multivessel PCI procedure is, when compared to single vessel procedure, 
associated with more TnT release. Furthermore, there is a trend towards a higher 
incidence of cardiac events during follow-up after a multivessel procedure. 
Whether a staged approach in patients with multivessel disease is associated 
with less events during follow-up has to be assessed. 
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Background: Although the prognostic importance of troponin in patients with an 
acute coronary syndrome is clear, the significance of troponin elevation after 
elective percutaneous coronary intervention (PCI) is subject of debate. However, 
most studies up to now had a small sample size and insufficient events during 
follow-up. 
 
Methods: Electronic and manual searches were performed of studies reporting 
on prognosis of troponin after elective PCI. A meta-analysis was done of all 
suitable studies, with death in follow-up as primary endpoint and the combination 
of death or non-fatal myocardial infarction in follow-up as secondary endpoint. 
 
Results: 20 studies involving 15,581 patients were included. These studies were 
published between 1998 and 2007. Overall, troponin was elevated after elective 
PCI in 32.9% of patients. The follow-up period varied between 3 and 67 months 
(mean 16.3). Increased mortality was significantly associated with troponin 
elevation after PCI (4.4% vs 3.3%, p =0.001; OR 1.35). Furthermore, the 
combined endpoint of mortality or non-fatal myocardial infarction occurred also 
more often in patients with post-procedural troponin elevation (8.1% vs 5.2%, p 
<0.001; OR 1.59). 
 
Conclusion: According to this meta-analysis, troponin elevation after elective PCI 






Cardiac-specific troponins are useful in establishing diagnosis and predicting 
prognosis in patients with (suspected) acute coronary syndromes (ACS). 
Moreover, the sensitivity, specificity and prognostic importance of troponin in ACS 
are superior compared to creatine kinase (CK) and its muscle-brain isomer (CK-
MB) [1-5]. 
After elective percutaneous coronary intervention (PCI), elevated cardiac 
enzymes can be observed frequently, even when the procedure is uncomplicated 
and successful. These elevations of cardiac enzymes have been associated with 
an increased risk of cardiac events, including death during follow-up, which has 
been shown clearly for CK and CK-MB in several studies [6-10]. Surprisingly, the 
association between troponin elevation after elective PCI and cardiac events 
during follow-up is less clear and conflicting results have been published on this 
topic [10-36]. However, especially in view of the paucity of outcome, the limitation 
of many of these studies is the sample size. Furthermore, because of the varying 
results of the previously performed studies, the results of a single study have to 
be interpreted with caution as well. 
To provide a better overall assessment of the prevalence and prognostic value of 
cardiac troponin elevation (I and T) after elective PCI in a large cohort, the 





We attempted to obtain results from all published studies on the association 
between troponin elevation after PCI and cardiac events and/or death in follow-
up. Both handsearching of the major general and cardiological journals and 
electronic searching was performed. The literature was scanned by formal search 
of electronic databases (MEDLINE, PubMed) using the keywords, “troponin”, 
“PCI”, “PTCA” and “follow-up”. Furthermore, we reviewed cited references of 
retrieved articles to identify all possibly relevant studies. 
We restricted our review to clinical trials and cohort studies with published data on 
events in follow-up. Studies that included patients with ST-elevation myocardial 
infarction as well as studies with severe restrictions for inclusion or exclusion of 
patients and studies published in a language other than English were excluded. 
The longest reported follow-up period was used. Furthermore, when more cut-off 
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values of troponin were used, the lowest available cut-off value was used. In 
studies reporting subgroups with elevated and non-elevated preprocedural 
troponin levels, only the subgroup with non-elevated troponin before PCI was 
included in our meta-analysis, as we were interested in data on elective PCI. 
Our primary efficacy of interest was the association between postprocedural 
troponin elevation and mortality during follow-up. Secondary, the association 
between troponin elevation and the occurrence of death or myocardial infarction 
(MI) during the follow-up period was investigated. 
Twenty-seven studies were identified initially, including also several studies with 
unavailable or inappropriate follow-up data. The primary endpoint in our meta-
analysis was not specifically reported in 4 studies [20,22,30,31]. In one older 
study with a very small sample size of 23 patients, an unusually high cut-off value 
for troponin T was used, and therefore this study was excluded [32]. Another 
small study on 83 patients had a poor methodology and a high percentage (23%) 
of patients lost to follow-up [33]. One previously performed meta-analysis was not 
useful, because of the use of study reports that were available as abstracts only 
[11]. After excluding these 7 studies, a total of 20 studies were finally suitable for 
our meta-analysis. 
Quantitative variables were expressed as percentages. Differences in outcome 
between patients with and without increased troponin were reported as odds ratio 
with 95% confidence intervals, by using the Mantel and Haenszel test. The freely 
available interactive statistic pages on http://statpages.org were used. A 





Twenty studies were included in our analysis [10,12-19,21,23-29,34-36], 
concerning 17 prospectively and 3 retrospectively performed studies. These 
studies were published between 1998 and 2007. The number of patients included 
in the studies varied between 44 and 3494, with a total number of 15,581. 
Glycoprotein IIb/IIIa receptor blockers were used in 39.8% of patients, a stent was 
placed in 80.6%, multivessel PCI was performed in 19.7% and postprocedural 
troponin was elevated in 32.9% of cases. Troponin I was measured in 14 studies, 
whereas 6 studies used troponin T; multiple cut-off values were used for both 
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In the individual studies, several predictors of postprocedural troponin elevation 
were identified. The most reported predictors were older age, poor LV function 
(EF <30%), unstable angina, ACC/AHA lesion type B and C, thrombus formation, 
balloon inflation time, stent implantation, atheroablative devices, abrupt vessel 
closure, no reflow, dissection and side branch occlusion. 
 
The follow-up period varied between 3 and 67 months (mean 16.3), the average 
percentage of patients lost to follow-up was 2%. The primary endpoint mortality 
was reported in all 20 included studies (table 2). 
 
 







n (%)  
Mortality and/or MI 
n (%)  
Author Troponin   
+ 











-   P 
Troponin I           
Attali 18 (41) 26 (59) 45 2 0 0 - - - - 
Bertinchant 18 (23) 61 (77) 19 25 0 0 - 0 1 (1.6) - 
Fuchs 345 (31) 784 (69) 8 12 8 (2) 19 (2) 0.74 9 (3) 21 (3) - 
Cantor 230 (48) 251 (52) 3 0 4 (1.8) 1 (0.4) 0.4 24 (10.6) 11 (4.2) 0.005 
Gruberg 50 (43) 66 (57) 12 0 14 (28.0) 7 (9.9) 0.002 17 (33.3) 9 (13.9) 0.002 
Saadeddin 26 (27) 70 (73) 24 0 1 (4) 0 - 1 (4) 0 - 
Nallamothu 336 (29) 821 (71) 11 0 30 (8.9) 61 (7.4) - - - - 
Ricciardi 36 (13.6) 227 (86.3) 12 3 3 (8) 16 (7) - 5 (14) 16 (7) - 
Kini 1121 (39) 1752 (61) 12 0 23 (2.0) 34 (1.9) 0.58 - - - 
Natarajan 189 (17) 939 (83) 12 0 4 (2.1) 9 (1.0) - - - - 
Ramirez 24 (16) 123 (84) 10 0 1 (4.2) 0 - 2 (8.3) 0 - 
Cavallini 1544 (44) 1950 (56) 24 0 75 (4.9) 78 (4.0) 0.2 - - - 
Okmen 34 (34) 66 (66) 21 0 1 (3) 2 (3) - 2 (6) 3 (4.5) - 
Izgi 27 (27) 73 (73) 12 0 0 1 (1) - 0 1 (1) - 
Troponin T           
Shyu 25 (21) 95 (79) 7 0 1 (4) 4 (4) - 1 (4) 4 (4) - 
Herrmann 44 (16) 225 (84) 6 3 4 (9.1) 2 (0.9) 0.001 5 (11) 3 (1) - 
Kizer 23 (18) 102 (82) 67 1 3 (13.0) 11 (10.8) - 5 (22) 16 (16) - 
Miller 507 (42) 691 (58) 12 10 12 (2.4) 9 (1.3) 0.52 24 (4.7) 20 (2.9) 0.16 
Prasad 383 (20) 1566 (80) 26 0 40 (10.4) 80 (5.1) <0.001 54 (14.1) 143 (9.1) 0.004 
Nienhuis 150 (21) 563 (79) 11 0 0 9 (1.6) 0.12 6 (4) 12 (2.1) 0.20 
Total         
(%) 























Figure 1. Odds ratio (95% CI) for death in pts with increased troponin. 
 
 
Average mortality was low (3.6%), but significantly higher in patients with troponin 
elevation after the PCI (4.4% vs 3.3%, p=0.001). The overall odds ratio for 
mortality according to postprocedural troponin elevation was 1.35 (95% CI 1.13-
1.60), as shown in figure 1. 
 
The combined endpoint of mortality or MI during follow-up was reported in 15 
studies. This combined endpoint was documented in 6.0% of patients and 
significantly more often in patients with postprocedural troponin elevation (8.1% 
vs 5.2%, p < 0.001). The odds ratio for the combined endpoint mortality or MI 
according to postprocedural troponin elevation was 1.59 (95% CI 1.29-1.95), as 
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The present meta-analysis shows a significant association between troponin 
elevation after elective PCI and mortality during follow-up. Furthermore, the 
combined endpoint of mortality or MI in follow-up was also associated with 
postprocedural troponin elevation. 
 
Included and other studies 
Previously, one meta-analysis was already performed on this topic, showing an 
association between troponin elevation and the occurrence of death and MI in 
follow-up [11]. However, that analysis included many studies that were published 
as abstracts only. Furthermore, baseline characteristics of the included patients 
were not reported and a large proportion of that meta-analysis data originated 
from 1 study. Moreover, the total number of included patients was only 2605, and 
more recent studies were not included. Cavallini et al showed in a large study on 
3494 patients a linear association between 2 years mortality and CK-MB 






All trials 1.59 (1.29 – 1.95) 
Shyu 









had an acute coronary syndrome. In these patients, elevation of troponin before 
PCI may have more prognostic importance than post procedural troponin 
elevations [27]. Remarkably, in studies with a large sample size, the association 
between troponin and cardiac events during follow-up was less clear than in 
studies with a small sample size [12,18,20,21,23-25]. This may be due to 
publication bias, as small studies with negative findings were possibly not 
published [37]. Specifically, 4 studies found an association between troponin and 
death and/or MI in follow-up [18,20,21,34], including a retrospective study of 
patients with chronic renal failure, but not on dialysis [21]. The results of this latter 
study have to be interpreted with caution, in view of the results of another recently 
published meta-analysis, showing a strong relation of asymptomatic troponin 
elevation and prognosis in patients on dialysis [38]. Two included studies 
investigated the clinical significance of troponin elevation in patients without 
concomitant CK-MB elevation [28,34]. Although in one study isolated troponin 
elevations did not predict cardiac events after hospital discharge, in the other 




There may be several causes for the adverse prognosis of patients with troponin 
rise after elective PCI. Multiple patient-related factors, including multivessel 
coronary artery disease, older age, interventions of de-novo lesions, sapheneous 
vein graft interventions and complex lesions have been related with troponin 
release after PCI, as well as procedure-related factors such as the no-reflow 
phenomenon, distal embolisation and side branch occlusion [39]. Studies with 
magnetic resonance imaging showed that even small increases of CK-MB or 
troponin are associated with new irreversible myocardial injury [40,41]. Another 
possible explanation for the worse prognosis of patients with troponin elevation is 
an increased inflammatory state [42]. 
The results of the studies performed with post-PCI CK (-MB) elevation were less 
varying than those with troponin, but most studies on CK (-MB) were performed in 
a larger sample size [6-10]. However, our meta-analysis showed clearly a 
significant association between troponin elevation and prognosis. Furthermore, as 
spontaneous elevation of troponin in patients with ACS is superior to CK (-MB) in 
predicting (future) cardiac events [1-5] and the adverse consequences of 
myocardial damage caused by PCI may be similar to spontaneous damage [8], 
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troponin might be superior to CK (-MB) after PCI in predicting cardiac events as 
well, although this has been debated [27]. 
 
Limitations 
Several limitations of our review should be noted. First, although there are 
differences between the types of troponin in e.g. sensitivity and specificity, we 
included studies on both troponin I and troponin T. Since there is no standard 
troponin I assay, we could not compare threshold values across studies. 
Furthermore, although there is a standard troponin T assay (Roche diagnostics), 
three different cut-off values were used. The total cohort represents a 
heterogenous mixture of patients undergoing elective PCI, for example 
balloon/stent implantation and single/multivessel PCI, and most of the included 
studies reported no detailed analyses of the subgroups. Especially PCI of 
saphenous vein bypass grafts, which has been shown to be strongly associated 
with more adverse in-hospital events and lower event-free survival compared to 
PCI of native arteries [43,44], was unfortunately not specified in most included 
studies. Therefore, we could not report prognostic value of troponin in subgroups. 
However, although this heterogenity could have influenced our results somehow, 
our principal conclusion presumably would be unaffected. Furthermore, as most 
studies did not report the number of patients with specific causes of 
postprocedural troponin elevation, a meta-analysis of these causes was not 
possible. Other potential reasons for troponin elevation, e.g. pulmonary embolism, 
renal failure were not, or only limited reported in the individual studies. The follow-
up periods in the included studies varied, and if prognostic value of troponin is 
time-dependent, this could have influenced the findings. Another limitation of our 
study is the chosen endpoint, which did not include target vessel revascularization 
during follow-up. However, as this latter endpoint was reported in only a few 
studies and may be considered as weak, for this meta-analysis only the hard 
endpoints death or MI were chosen. Because not all included studies focused on 
the same endpoint, from some studies we only used a part of the reported results. 
Finally, potential under-reporting of negative studies may have increased the 
strength of association between troponin and outcome.
 
 
Conclusion and implications 
The use of troponin after elective PCI is not recommended by the recently revised 
European guidelines [45], based on only 3 studies and the previously performed 
meta-analysis with the already mentioned important limitations [11]. Routine 
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measurement of troponin and/or CK-MB seems to be reasonable according to the 
recently revised ACC/AHA guidelines, whereas determining these biomarkers is 
advised for patients with signs or symptoms suggestive of MI or angiographic 
evidence of complications after PCI [46]. According to the results of our meta-
analysis, cardiac troponins offer important prognostic information after elective 
PCI. The remaining questions are whether troponin has to be used in daily 
practise next to, or instead of CK(-MB) and whether determining troponin can be 
cost-effective. Furthermore, still have to be determined whether more intensive 
monitoring and treatment of patients with increased troponin after elective PCI will 
reduce future cardiac events. 
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Background: In patients with ST-segment elevation acute myocardial infarction 
(STEMI), elevated cardiac troponin T (cTnT) on admission is associated with 
poorer outcomes despite early reperfusion. Presentation delay is thought to the 
be most important factor for the elevation of cTnT on admission. We evaluated 
presentation delay and other potential predictors of elevated cTnT on admission 
in patients treated with primary percutaneous coronary interventions (PCI) for 
STEMI. 
 
Methods: CTnT was measured upon arrival in the PCI centre in 444 patients with 
acute STEMI. An elevated cTnT was defined as > 0.05 µg/L. 
 
Results: Mean age was 61.7 year and the patients were admitted after a median 
of 155 minutes after symptom onset. Almost 50% had an elevated cTnT on 
admission. Patients with a positive cTnT on admission had less often successful 
primary PCI (87% vs. 93%, p=0.048) and significantly higher rates of one year 
mortality (4.9% vs. 1.3%, p=0.031). There was a significant association between 
presentation delay and the prevalence of elevated admission cTnT, but even 
patients with early presentation (<120 minutes after symptom onset) still had a 
high prevalence of elevated cTnT (33%). After multivariate analysis, apart from 
presentation delay, anterior myocardial infarction (MI) location and higher age 
were independent predictors of elevated cTnT on admission. 
 
Conclusion: In patients with STEMI, the prevalence of elevated cTnT on 
admission is high, even in patients with early presentation. Independent 
predictors of elevated cTnT on admission are presentation delay, increasing age 





Several studies have demonstrated that an elevated cardiac troponin T (cTnT) on 
admission in patients with ST-segment elevation myocardial infarction (STEMI), 
predicts short- and long term mortality and failure of thrombolytic therapy or 
primary percutaneous coronary interventions (PCI) [1-5]. Giannitsis et al [6] found 
that elevated cTnT on admission in STEMI predicts lower rates of post procedural 
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow, more severely 
compromised myocardial perfusion despite normal epicardial flow and higher 
rates of all cause and cardiac mortality. They also concluded that cTnT-positive 
patients might require more aggressive adjunctive therapy when treated with 
primary PCI. Although cTnT may be elevated even within 2 hours after symptom 
onset [3,6], it is generally believed that cTnT elevations are mostly seen at a 
minimum of 3-4 hours after the onset of chest pain [7]. 
Previous reports were hampered by relative small sample sizes and predictors of 
elevated cTnT on admission are not yet clear. The present study was designed to 
identify the independent predictors of elevated cTnT on admission in a large 
population of STEMI patients treated with primary PCI and to study the 
mechanism of cTnT elevation early after symptom onset.   
 
 
Patients and Methods 
 
From June 2001 to November 2002, 507 consecutive patients were enrolled in 
the On-TIME trial. Patients with STEMI, who were transferred to a PCI centre, 
were randomised to early (pre-hospital) or late (in the catheterization laboratory) 
initiation of tirofiban. Inclusion and exclusion criteria have been described 
previously [8]. In brief: patients with chest pain of > 30 minutes' duration and ECG 
changes with ST segment elevation > 2 mm in the precordial leads or >1 mm in 
the limb leads in at least 2 contiguous leads were included in the study. The 
ability to perform PCI within 6 hours after symptom onset was also an enrolment 
criterion. The exclusion criteria were age over 80 years, women less than 50 
years of age, patients who were treated with thrombolytic therapy in the previous 
24 hours, patients on warfarin or acenocoumarol within the last 7 days and 
patients with a contraindication to glycoprotein IIb/IIIa blockade. Patients with 
severe heart failure or cardiogenic shock and patients who were on hemodialysis 
were also excluded. 
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Each institution’s Review Board or Ethical Committee approved this study. All 
patients gave written informed consent. The study population consisted of 444 
patients (88%), by whom cTnT was measured on admission. Patients were 
stratified into cTnT-positive and cTnT-negative. Baseline characteristics, 
angiographic parameters and clinical outcome were compared between the cTnT-
positive and cTnT-negative patients. Presentation delay was defined as the time 
from symptom onset to infarct diagnosis (first ECG). Ischemic time was defined 
as time from symptom onset to first balloon inflation.  
 
Serum marker analyses  
CTnT levels were measured by using a point-of-care system (Cardiac reader, 
Roche Diagnostics, Almere, Netherlands). CTnT > 0.05 µg/L was considered as 
positive. Creatine kinase (CK), creatine kinase MB (CK-MB) activity and 
cumulative Lactate Dehydrogenase (LDHQ48) concentrations were analysed with 
the Elecsys 2010 system (Roche Diagnostics). Glucose was measured by a 
hexokinase method using a Modular PPE module device (Roche Analytics, 
Almere, Netherlands). High sensitivity C-reactive protein (HsCRP) was measured 
by immunochemical analyses of HsCRP (Modular, Roche, Almere, Netherlands) 
and the White blood cell count (WBC) is determined on the Sysmex XE 2100 
(Goffin Meyvis, Etten-Leur, Netherlands). 
To evaluate the relation between symptom onset to admission time and elevating 
cTnT, we stratified the patients according to presentation delay in an early group 
who presented within 120 min after the onset of symptoms, an intermediate 
group, who presented between 120 and 180 minutes and a late group who 
presented later than 180 minutes.  
 
Angiographic data analysis 
All angiograms were analyzed by an independent core lab (Diagram B.V., Zwolle, 
The Netherlands) who were blinded to all data. Apart from the coronary 
angiogram; TIMI flow grades and myocardial blush grade (MBG) were assessed 
after the angioplasty procedure, as previously described [9,10]. Residual stenosis 
was assessed visually. Procedural success was defined as postprocedural TIMI 3 
flow of the infarct related vessel (IRV) and residual stenosis less than 50%. Left 







For assessment of ST-segment resolution, serial 12-lead ECG recordings just 
before PCI and immediately after return to the coronary care unit were analysed 
by the same core lab blinded to the clinical data. ECG’s with bundle-branch block, 
pacemaker rhythm, or incomplete or poorly interpretable ECG recordings were 
not included in this analysis. The ST segment in the lead showing maximal 
deviation was measured 60 ms after the J point. The resolution of the ST 




Records of included patients who visited our outpatient clinic were reviewed. For 
all other patients, information was obtained from the patient's general physician or 
by direct telephone interview with the patient. For patients who died during follow-
up, hospital records and necropsy data were reviewed. Patients were followed up 
prospectively for one year by use of hospital records, questionnaire, and 
telephone contact.  
 
Statistical analysis  
Statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were 
expressed as mean ± standard deviation of mean or median and 25-75 percentile 
and categorical data as percentage, unless otherwise denoted. The analysis of 
variance and the chi-square test were appropriately used for continuous and 
categorical variables respectively. A multivariate logistic regression analysis was 
performed to identify independent predictors of high troponin level at admission. 
Significant variables analyzed are reported with their respective odd ratios and 
95% confidence intervals. For all analyses, statistical significance was assumed 






CTnT on admission was measured in 444 patients. Mean age of these patients 
was 61.7 years and they were admitted after a median of 155 minutes after 
symptom onset. Almost 50% of the patients had an elevated cTnT on admission.  
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Clinical characteristics of the study group stratified by admission cTnT are 
displayed in table 1. Patients with elevated cTnT on admission were significantly 
older, more often female, had more often a heart rate >100 bpm or an anterior 
myocardial infarct location. Presentation delay (median 106 vs. 80 min.) was 
longer and Killip class > 1 was significantly more often present in the cTnT 




Table 1. General Characteristics.                                                                     
cTnT-positive  cTnT-negative p-value 
Variable             (n=208, 47%)  (n=236, 53%)    
Age (years ± sd)   64 ± 11       60 ± 10  < 0.001 
Female gender n, (%)   49 (24)          37 (16)  0.04 
Diabetes mellitus, n (%)  26 (13)        18 (8)   0.09 
Hypertension, n (%)   60 (29)  64 (27)  0.7 
Hyperlipidemia, n (%)   42 (20)  61 (26)  0.2 
Smoking, n (%)   128 (62)  150 (65)  0.5 
Heart rate >100 bpm, n (%)  26 (13)                  8 (4)   < 0.001 
Previous MI, n (%)   14 (7)    25 (11)        0.2 
Previous PCI, n (%)   7 (3)   17 (7)          0.08  
Previous CABG, n (%)  3 (1)   8 (3)   0.2 
Anterior infarction, n (%)   115 (57)         75 (34)  < 0.001 
Presentation delay (min)  106 (63-182)  80 (50-128)  < 0.001 
Killip class >1, n (%)   42 (22)  23 (11)  0.003  
Glucose (± SD)   9.92 (3.77)  9.46 (2.58)  0.1 
CK on admission U/L   190 (125-348)  98 (70-148)             < 0.001 
CK peak U/L,    1879 (804-3889) 1489 (661-3027)   0.007 
CK-MB on admission U/L  21 (14-38)  12 (9-15)             < 0.001 
CK-MB peak U/L   229 (89-425)  189 (76-307)             < 0.001 
LDHQ48    1419 (439-2838) 1093 (441-2119) 0.10 
WBC 109/L    11.8 ± 3.5  11.9 ± 3.6  0.8 
HsCRP, mg/L    3.1 (1.4-6.0)  2.3 (1.3-4.5)  0.02 
Early tirofiban initiation, n (%) 112 (54)  106 (45)  0.06 
Cum. ST-elevation (mm) (± SD) 11 ± 8   9.5 ± 7   0.07 
ST resolution, % (± SD)  73 ± 29  74 ± 39  0.9  
Values given as means with SD in parentheses or as absolute numbers with relative 
frequencies. Presentation delay, CK, CK-MB, LDHQ48 and HsCRP are given as median and 
25-75 percentile. LDHQ48 = Enzymatic infarct size (area under the lactate dehydrogenase 









Admission CK and CK-MB were significantly higher in the cTnT positive patients. 
WBC was comparable in both groups but HsCRP was significantly higher in the 
cTnT positive patients. Prevalence of elevated admission cTnT was 33% in the 
early, 46% in the intermediate and 62% in the group with long presentation delay 
(figure 1). Prevalence of increased cTnT was 54% in the early tirofiban group, 
compared to 46% in the late tirofiban group (p =0.06). 
 
Angiographic findings 
Multivessel disease and thrombus load were comparable in cTnT positive- and 
cTnT negative patients (56% vs. 54% and 31% vs. 27%, respectively) (table 2). 
Pre PCI TIMI 3 and TIMI 2,3 were significantly higher in the cTnT positive patients 
(21% vs. 13%, p =0.03 and 45% vs. 32%, p =0.008, respectively). Both post PCI 
TIMI 3 flow and MBG 3 were significantly lower in the cTnT positive patients (87% 
vs. 93%, p =0.048 and 42% vs. 63%, p <0.001, respectively). LVEF was 
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Figure 1. Prevalence of elevated cTnT on admission according to time from symptom onset to 
admission. 
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Table 2. Angiograpic parameters pre- and post PCI. 
              cTnT positive       cTnT negative         p-value 
Variable             (n=208, 47%)  (n=236, 53%)                   
Pre-PCI 
Multivessel Disease, n (%) 115 (56)  122 (54)  0.7 
TIMI 3    43 (21)  29 (13)  0.03 
 TIMI 2,3   92 (45)  72 (32)  0.008 
 Thrombus   63 (31)  60 (27)  0.4 
Post-PCI  
TIMI 3     161 (87)  197 (93)  0.048 
MBG 3    78 (42)  132 (63)          <0.001 
Coronary stenting, n (%)  127 (69)  153 (74)  0.3 
LVEF     42 ± 12  47 ± 9           <0.001 
TIMI = thrombolysis in myocardial infarction, MBG = myocardial blush grade 
 
 
Infarct size and outcome 
LDHQ48 and cumulative ST- segment elevation tended to be higher in the cTnT 
positive patients. No significant difference was found in ST segment resolution 
between cTnT positive and cTnT negative patients (table 1).  
At 30 days, cardiac and all-cause mortality tended to be higher in the cTnT 
positive patients. At one year, cardiac death (3.4% vs. 0.4%, p =0.03) and all-
cause mortality (4.9% vs. 1.3%, p =0.03) were significantly higher in cTnT positive 
patients. Rates of combined reinfarction and/or death were not statistically 
different in both groups (figure 2). 
 
Multivariate analysis 
To assess the independent predictors of an elevated cTnT on admission, we 
performed a multivariate analysis and included age, gender, infarct location, Killip 
class, diabetes, previous PCI, heart rate>100 bpm, Hs CRP and presentation 
delay. Age (years), Hs CRP (mg/ml) and presentation delay (minutes) were 
included as continuous variables. Multivariate analysis revealed that age, (OR 
1.03; 95%CI: 1.01-1.06, p =0.01), anterior myocardial infarction (OR 2.98; 95%CI: 
1.78-4.99, p <0.001) and presentation delay per 30 minutes (OR 1.23; 95%CI: 
1.10-1.34, p <0.001) were independent predictors of an elevated cTnT on 


































































Figure 2. Short- and long-term outcomes. At 30 days rates of cardiac death and all causes of 
mortality were not significantly different between both groups. However, at one year rates of 




Table 3. Predictors of troponin T elevation, multivariate analysis. 
Variable     OR  95% CI   P  
Age (per year)    1.03  1.01-1.06  0.01 
Anterior infarction    2.98  1.78-4.99  < 0.001 
Presentation Delay (per 30 min.)  1.23  1.10-1.34  < 0.001 
Diabetes     0.64  0.25-1.06  0.3 
Previous PCI     0.31  0.09-1.05  0.06 
Female gender    1.41  0.72-2.76  0.3 
Heart rate >100 bpm    4.74  0.81-27.6  0.08  
Killip class >1      1.86  0.72-4.76  0.2 
Hs CRP (per mg/L)    1.01  0.99-1.40  0.2 
Hs CRP = high-sensitive C-reactive protein 
 
 




This study demonstrates that apart from presentation delay, anterior myocardial 
infarct location and higher age are also independent predictors of elevated 
cardiac troponin T on admission. Elevated cTnT on admission is associated with 
worse angiographic and clinical outcome, despite primary PCI and treatment with 
tirofiban.  
 
Predictors of elevated cTnT on admission  
Our data show that in patients with STEMI, cTnT identifies a high risk group, 
characterized by Killip class > 1, elderly and patients with anterior myocardial 
infarct location. A previous study [7] emphasized that troponin T elevations are 
only seen at a minimum 3-4 hours after the onset of symptoms. Other studies, 
however, reported an elevated TnT on admission even within 2 hours after 
symptom onset [3,6]. 
We consistently found that admission delay was associated with elevated 
troponin on admission [6]. Nevertheless, almost 50% of the patients had an 
elevated cTnT on admission, whereas even patients with short presentation delay 
(<120 minutes after symptom onset) had a relatively high prevalence of elevated 
cTnT (33%). Why patients with short symptom duration would have an elevated 
cTnT on admission is not yet clear. In these patients the onset of symptom may 
have gone undetected and thus the true onset of the infarction could have begun 
much earlier. They could have had a previous silent event that caused cTnT 
release [3]. Previous study reported that acute coronary occlusion in STEMI, is 
often the final stage in a series of successive events that occurred in the 
preceding days or weeks [11]. Other possible explanation of elevated cTnT short 
after symptom onset is a large area at risk, cTnT positive patients had higher 
levels of peak CK-MB and lower LVEF (table 1, table 2). Furthermore, the 
absence of collaterals may also explain the elevated troponin on admission. 
Matetzky et al found that patients with elevated troponin have less frequently 
collateral blood flow [5]. In addition, in the current study patients with elevated 
cTnT on admission more often had a Killip class>1 and we previously reported 
that a Killip class > 1 is associated with worse outcome in STEMI patients [12].  
 
Prognostic value 
Previous studies have demonstrated that both thrombolysis and primary PCI 
therapy are less effective in cTnT positive patients [2,4,5,13]. Others have found 
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that epicardial flow (TIMI flow <3) remained more frequently compromised and 
myocardial reperfusion (as measured by serum cardiac markers) was more 
impaired in cTnT-positive than in cTnT-negative patients [6].  
Our data confirm that elevated cTnT is associated with impaired myocardial 
perfusion, as measured by MBG, and lower rates of post-PCI epicardial TIMI 3 
flow. Previous studies [14,15] showed that pre-procedural patency (TIMI 2 or 3) is 
associated with favorable outcome. In our study we found that outcome was 
worse in cTnT positive patients, although these patients had higher initial patency 
rate of the infarct related vessel (IRV). This may be caused by early washout of 
cardiac enzymes in patients who presented with open IRV (table 2). In addition, 
the higher rates of TIMI 3 flow in cTnT positive patients could also be explained 
by the higher rates of anterior myocardial infarct location (table 1), since it has 
been found that patients with an anterior myocardial infarct location more often 
have a patent IRV than non anterior infarct location [16]. In addition, our study 
confirms the results of a previous study [17] that found an inverse relation 
between LVEF and cTnT. Furthermore, our results are consistent with Kurowski 
et al, who found a poorer outcome in patients with elevated troponin as compared 
to patients with normal troponin values on admission [18]. 
 
Implication for treatment 
Because elevated cTnT on admission have a worse prognosis, efforts should be 
made to improve their treatment. Although in a general population with STEMI 
treated with primary PCI and coronary stenting, glycoprotein IIb/IIIa inhibitors 
have limited value [19], in patients with elevated cTnT on admission there may be 
more clear effects.  
 
Limitations 
This study is a post-hoc, observational analysis and the results were obtained in 
patients who underwent primary PCI and may not relate to patients treated with 
thrombolytic therapy. Second, troponin T was measured using a point-of-care 
reader allowing only identifying patients with troponin levels above 0.05 µg/L. 
However, by definition, patients with levels above 0.03 µg/L are classified as non-
STEMI and increased risk has been reported by the TACTICS TIMI 18 Study 
Group even at levels close to the lower detection limit [20]. Thus, it is likely that 
the On-Time study has underestimated the true proportion and risk in this subset. 
Nevertheless, studies using higher cut-off values found similar results [3,6]. 
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Another limitation is that we measured CK-MB activity and not CK-MB mass, 
however, CK-MB mass is more sensitive and more specific.  
 
Conclusion 
This study shows a high prevalence of elevated cardiac troponin T on admission  
in patients with STEMI treated with primary PCI, even in patients who presented 
early after symptom onset. Apart from presentation delay, increasing age and 
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Background: Although the prognostic significance of CK and CK-MB after 
myocardial infarction has been established after thrombolysis or no reperfusion 
therapy, there is limited evidence of the prognostic importance after primary 
percutaneous coronary intervention (PCI). 
 
Methods: In this prospective, observational study, individual data from all patients 
who survived at least 2 days after primary PCI between 1991 and 2004 in our 
hospital were recorded. The association between enzymatic infarct size 
(examined by peak CK and peak CK-MB levels, each divided into tertiles) and 
both LV ejection fraction and one-year mortality was evaluated. 
 
Results: In the study group of 4670 patients, mean peak CK was 2327 U/L 
(SD±2008) and mean peak CK-MB was 244 U/L (SD±208). Both increased CK 
and CK-MB were associated with a lower LV ejection fraction. A total of 252 
patients (5.4%) died between 2 days and one year after admission. Both peak CK 
and peak CK-MB were higher in those who died. Particularly, patients in the 
highest tertile of either peak CK or peak CK-MB had increased mortality, whereas 
the differences between the lower tertiles were not significant. In 2738 patients, 
after multivariable analysis including LV ejection fraction, the hazard ratio for one-
year mortality in patients in the highest CK tertile was 2.28 (95% CI 1.32-3.91) 
and for CK-MB 1.91 (95% CI 1.11-3.26), compared to those in the other tertiles. 
 
Conclusion: According to this large-scale study, peak CK and peak CK-MB are 
comparable independent predictors of LV-function and one-year mortality in 





The adverse prognostic significance of biomarker elevations during myocardial 
infarction (MI) has been subject for many studies in the past decades. Peak levels 
of aspartate aminotransferase (ASAT), lactate dehydrogenase (LDH), creatine 
kinase (CK) and its muscle brain isomer (CK-MB) have been shown to be reliable 
predictors of infarct size and prognosis in patients suffering MI [1-7]. Furthermore, 
the cumulative CK and LDH curve areas are also well correlated with infarct size 
[8,9]. 
Over the past years, primary percutaneous coronary intervention (PCI) has 
become the preferred therapy for patients with ST-elevation myocardial infarction 
(STEMI) [10,11]. However, the above mentioned studies on biomarkers have 
been performed in patients receiving thrombolytics or no reperfusion therapy at 
all. Only two large-scale studies have been published in patients undergoing 
primary PCI for STEMI, one showing that the cumulative extent of LDH is an 
independent predictor of one-year mortality [12] and the other that peak CK level 
is associated with increased one-year mortality [13]. The latter study, however, 
did not assess the potential importance of CK-MB. 
To address this issue, we performed a prospective study on patients undergoing 
primary PCI for STEMI, focusing on both peak CK and CK-MB levels and their 






From January 1991 to December 2004, individual patient data from all patients 
with admission diagnosis of STEMI admitted for primary PCI at the Isala klinieken 
(Zwolle, the Netherlands) were prospectively recorded. Patients who died during 
the first 2 days were not included in this sub-study, because many of these 
patients died before peak CK was recorded. Furthermore, patients with peak CK 
values > 10.000 U/L were excluded, as these high elevations of CK were probably 
at least partly due to rhabdomyolysis. To avoid double inclusion of patients, only 
the first recorded admission for STEMI during the study period was used. Patients 
were diagnosed with STEMI if they had chest pain of > 30 minutes' duration and 
ECG changes with ST segment elevation > 2 mm in at least 2 precordials and > 1 
mm in the limb leads. Before the primary PCI procedure, all patients received 500 
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mg of aspirin and 5000 IU of heparin intravenously. Primary PCI was performed 
with standard techniques if the coronary anatomy was suitable for angioplasty. 
PCI success was determined by the classification system of the Thrombolysis in 
Myocardial Infarction (TIMI) trial, in which a grade 3 blood flow indicates normal 
flow within the vessel, in combination with a myocardial blush grade 2 and 3 [14]. 
Additional treatment with GP IIb/IIIa-inhibitors or stents was to the discretion of 
the treating cardiologist. All patients were treated with optimized drug-therapy 
including angiotensin-converting enzyme inhibitors, β-blockers, aspirin and lipid-
lowering drugs where appropriate. 
 
Measurements 
Protocol-specified blood sampling for CK and CK-MB levels was performed at 
baseline and at 8 hours, 16 hours and 24 hours after PCI. Measurement of serum 
total CK and CK-MB levels was performed according to our local hospital 
standards, which did not change over the course of the study. LVEF was 
measured before discharge by radionuclide ventriculography or by 
echocardiography if the patient had atrial fibrillation. Radionuclide 
ventriculography was performed by using the multiple gated equilibrium method 
following the labelling of red blood cells of the patient with 99mTc-pertechnate. A 
General Electric 300 gamma camera with a low-energy all-purpose parallel-hole 
collimator was used. Global ejection fraction was calculated by a General Electric 
Star View computer using the fully automatic PAGE program. In patients with 
atrial fibrillation, standard 2-dimensional and Doppler imaging was performed and 
stored in cineloop format by well-trained echocardiographists and reviewed by 
experienced cardiologists. The LV end-diastolic volume (LVEDV) and end-systolic 
volume (LVESV) were measured [15] and the LV ejection fraction was calculated 
as (LVEDV-LVESV)/LVEDV x 100% (Simpson’s rule). A low LVEF was defined as 
an ejection fraction ≤ 30%. Ischemic time was defined as time from symptom 
onset to first balloon inflation. The definition of multivessel disease was a stenosis 
in at least one non-culprit coronary artery of more than 50%, as judged by 2 
experienced cardiologists or by quantitative coronary analysis. 
Follow-up information was obtained from the patient's general physician or by 
direct telephone interview with the patient or it’s relatives. Events were confirmed 
by reviewing the concerning letter to the general physician or patient’s clinical file 
if necessary, and all cause mortality was reported. Re-MI was defined as anginal 
complaints with new CK(-MB) elevation and/or new Q-waves on the 
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electrocardiogram in follow-up. Study approval was obtained from the medical 
ethic committee of our hospital. 
 
Statistical Analysis  
Statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Outcomes were 
examined stratified by peak CK and peak CK-MB levels, divided into three equal 
tertiles. Univariate differences between groups were analyzed with one-way 
analysis of variance or by chi square test as appropriate, with Bonferroni 
correction for multiple comparisons. Cox proportional-hazards regression models 
were used to estimate the risk of mortality after one year. Separate analyses were 
performed in patients with known LV ejection fraction, since 41% of these data 
were missing. Multivariable analyses were performed with the Cox models for all 
cause mortality and with a logistic regression model to assess risk of low LV 
ejection fraction. In this analysis, patients in the highest tertile of CK or CK-MB 
were compared to those in the lower tertiles. Significant variables analysed are 
reported with their respective hazard ratios (HR) and 95% confidence intervals 
(CI). For all analyses, statistical significance was assumed when the two-tailed 





Baseline characteristics  
Of the 4670 included patients, mean age was 60.8 years (SD 11.8) and 1102 
patients (24%) were female. Data on peak CK and peak CK-MB were available in 
all patients. Mean peak CK was 2327 U/L (SD 2008) and mean CK-MB 244 (SD 
208). The range in the 3 tertiles was respectively <1080 U/L, 1080-2660 U/L and 
>2660 U/L for CK, and <120 U/L, 120-281 U/L and >281 U/L for CK-MB. 
Differences of the baseline characteristics between the tertiles of CK are 
summarised in table 1 and of CK-MB in table 2. Patients with higher peak CK and 
peak CK-MB values were more likely to be younger and smoker, but were less 
likely to have previous history of coronary bypass surgery, PCI or MI. Patients 
with higher peak CK (-MB) values also had more often anterior infarction, higher 
Killip class on presentation, TIMI 0 flow pre-PCI and less often TIMI 3 flow post-
PCI. 
 




Data on LVEF were available in 2738 patients (59%). Patients in the medium and 
highest tertile of CK and CK-MB had significantly lower LVEF and a longer 
hospital stay compared to patients in the lowest tertile, as shown in table 3 and 






Table 1. Baseline characteristics according to tertiles of peak CK in 4670 pts who survived at 
least 2 days after primary PCI for ST-elevation MI. 
Variables    Lowest  Medium  Highest       
     n = 1554  n = 1560  n = 1556   
 
Age, yr±sd   62.2±11.5  61.6±11.9   59.4±12.0 #  
Female gender  429 (28%)  377 (24%)  296 (19%) ^  
History of 
 MI   225 (15%)  185 (12%)  154 (10%) #  
 CABG   62 (4%)  48 (3%)  29 (2%) #  
 PCI   116 (8%)  104 (7%)   65 (4%) #  
 Stroke   57 (4%)  40 (3%)  55 (4%)  
 Hypertension  477 (31%)  424 (28%)  431 (28%)  
 Diabetes  190 (12%)  138 (9%) *  167 (11%)  
 Hyperlipidemia 338 (23%)  333 (23%)  287 (20%)  
 Family  CVD  639 (43%)  648 (43%)  651 (43%)  
 Smoke   674 (44%)  715 (47%)  849 (56%) #  
Killip class > 1  88 (6%)  123 (8%)  217 (14%) # 
Ischemic time, hr±sd  4.6±5.7  5.0±6.8  4.7±4.6 
Anterior MI   668 (44%)   617 (40%)  984 (63%) #   
Multivessel disease  771 (51%)  853 (56%) $  805 (52%)  
TIMI 0 flow pre-PCI  536 (39%)  1010 (68%) #  1161 (78%) #  
Stent implantation  749 (54%)  789 (53%)  907 (60%) ^ 
TIMI 3 flow post-PCI  1250 (91%)  1295 (87%) $     1284 (86%) # 
  
$ p < 0.05; * p < 0.01; ^ p < 0.005; # p < 0.001 compared to lowest tertile 




Table 2. Baseline characteristics according to tertiles of peak CK- MB in 4670 pts who 
survived at least 2 days after primary PCI for ST-elevation MI.  
 
Variables    Lowest  Medium  Highest       
     n = 1541  n = 1554  n = 1575   
 
Age, yr±sd   61.6±11.6  61.3±11.9  60.4±12.1 $  
Female gender  385 (25%)  365 (24%)  352 (22%)  
History of 
 MI   236 (15%)  185 (12%) $  143 (9%) #  
 CABG   61 (4%)  49 (3%)  29 (2%) #  
 PCI   119 (8%)  101 (7%)  65 (4%) #  
 Stroke   56 (4%)  34 (2%)  62 (4%)  
 Hypertension  469 (31%)  434 (28%)  429 (28%)  
 Diabetes  174 (11%)  163 (11%)  157 (10%)  
 Hyperlipidemia 346 (24%)  332 (23%)  280 (19%) ^  
 Family  CVD  633 (43%)  664 (44%)  640 (42%)  
 Smoke   671 (44%)  729 (48%)  837 (55%) #  
Killip class > 1  99 (7%)  121 (8%)   207 (13%) # 
Ischemic time, hr±sd  4.7±6.4  4.5±4.2  5.1±2.9  
Anterior MI   668 (44%)   624 (40%)   976 (62%) #   
Multivessel disease  767 (51%)  840 (55%)   821 (53%)  
TIMI 0 flow pre-PCI  522 (39%)  983 (66%) #  1201 (79%) #  
Stent implantation  720 (52%)  790 (53%)  935 (61%) # 
TIMI 3 flow post-PCI  1220 (91%)  1315 (88%)  1293 (85%) #  
  
$ p < 0.05; ^ p < 0.005; # p < 0.001 compared to lowest tertile 




Table 3. Prognosis according to tertiles of peak CK in 4670 pts who survived at least 2 days 
after primary PCI for ST-elevation MI. 
 
Variables    Lowest  Medium  Highest       
     n = 1554  n = 1560  n = 1556  
 
Mean LVEF (%)  50.5±10.9  46.8±10.3 #  38.5±11.1 # 
Mean hospital stay (days) 4.7±7.0  5.2±5.7 $  5.5±6.4 # 
Outcome after one-year: 
Death   57 (4%)   63 (4%)  132 (9%) #   
Death/re-MI  118 (8%)  132 (8%)  195 (13%) #  
Stroke   12 (1%)  18 (1%)  15 (1%)  
CABG   200 (13%)  219 (14%)  186 (12%)  
PCI   218 (14%)  248 (16%)  237 (15%) 
re-MI   66 (4%)  75 (5%)  82 (5%) 
 
$ p < 0.05; # p < 0.001 compared to lowest tertile 
p-values adjusted for multiple comparisons 




Table 4. Prognosis according to tertiles of peak CK-MB in 4670 pts who survived at least 2 
days after primary PCI for ST-elevation MI.  
 
Variables    Lowest  Medium  Highest       
     n = 1541  n = 1554  n = 1575 
 
Mean LVEF (%)  50.8±10.7  46.5±10.4 #  38.4±11.1 # 
Mean hospital stay (days) 4.7±6.6  5.5±6.3 ^  5.3±6.3 $ 
Outcome after one-year: 
Death   57 (4%)   58 (4%)  137 (9%) #   
 Death/re-MI  114 (7%)  131 (8%)  200 (13%) #  
Stroke   12 (1%)  12 (1%)  21 (1%)  
CABG   211 (14%)  211 (14%)  183 (12%) 
PCI   216 (14%)  261 (17%) $  225 (14%) 
re-MI   62 (4%)  81 (5%)  80 (5%) 
 
$ p < 0.05; ^ p < 0.005; # p < 0.001 compared to lowest tertile 



























As no patients were lost to follow-up, data on one-year mortality were available in 
all 4670 patients. A total of 252 patients (5.4%) died between 2 days and one 
year after admission. Mean CK in patients who died within one-year was 3268 
U/L (SD 2461) compared to 2273 U/L (SD 1966) in those who survived (p 
<0.001). Mean CK-MB was 359 U/L (SD 268) in those who died within one year, 
compared to 238 U/L (SD 202) in patients who were alive after one year (p 
<0.001). Survival curves of patients in the different CK or CK-MB tertiles are 
depicted in figure 2 and figure 3. Patients in the highest tertile of CK had an 
increased risk of one-year mortality, HR 2.3 (95% CI 1.77-2.90) compared to 
those in the other tertiles. However, one-year mortality was not different between 
patients in the two lower tertiles of CK (p=0.59). Patients in the highest tertile of 
CK-MB had also an increased one-year mortality, HR 2.41 (95% CI 1.88–3.09). In 
the two lower tertiles of CK-MB, there was also no significant difference in one-




Figure 2. One-year mortality according to tertiles of peak CK in 4670 pts who survived at 
least 2 days after primary PCI for ST-elevation MI, p <0.001 for the highest tertile as 
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Figure 3. One-year mortality according to tertiles of peak CK-MB in 4670 pts who survived at 
least 2 days after primary PCI for ST-elevation MI, p <0.001 for the highest tertile as 




In 2738 patients, the unadjusted HR for developing a low LVEF was 5.76 (95% CI 
4.51-7.35) of patients in the highest tertile of CK and 5.49 (95% CI 4.31-6.99) of 
patients in the highest tertile of CK-MB. After adjusting for age, gender, infarct 
location, Killip classification on admission, previous MI, stent implantation, 
multivessel disease and TIMI flow post PCI, the HR in patients in the highest 
tertile of CK was 4.61 (95% CI 3.48-6.09) and of patients in the highest tertile of 
CK-MB 4.35 (3.31-5.74). 
After adjusting for differences in age and gender in the total study group of 4670 
patients, both patients in the highest tertile of CK, HR 1.79 (95% CI 1.52–2.10) 
and the highest tertile of CK-MB, HR 1.71 (95% CI 1.46–2.01) had an increased 
one-year mortality. After adjusting for differences in age, gender, infarct location, 
Killip classification on admission, multivessel disease, previous MI, stent 
implantation and TIMI flow post PCI, the HR in patients in the highest CK tertile 
was 2.06 (95% CI 1.54–2.76) and of patients in the highest CK-MB tertile 2.16 
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LVEF was available (n=2738), the HR of one-year mortality in patients in the 
highest tertile of CK was 2.28 (95% CI 1.32-3.91) and of patients in the highest 
tertile of CK-MB 1.91 (95% CI 1.11-3.26) (figure 4). 
 
 
Figure 4. Adjusted and unadjusted hazard ratios (95% CI) for 1-yr mortality or a low LV 






The present study shows that both peak CK and peak CK-MB are comparable 
independent predictors of LV ejection fraction and one-year mortality in patients 
after primary PCI for STEMI. Furthermore, particularly patients in the highest 
tertiles of either CK or CK-MB had a poor prognosis, whereas the differences 
between the lower tertiles were less clear. 
 
Previous literature 
Since the 1970’s, the association between peak CK, infarct size and mortality has 
been recognized [1,2]. Although some doubt was raised about the association 
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between CK and long-term mortality in some studies [3,4], the association was 
confirmed for several types of acute coronary syndromes (ACS), including 
patients without ST-segment elevation and patients treated with thrombolytic 
therapy [5]. 
After recognition of the importance of CK, the additional significance of the isomer 
CK-MB was identified [6,7,16]. In a large trial was shown that in patients with ACS 
without ST-segment elevation, minor elevations of CK-MB were related to 
increased mortality [17]. Moreover, also CK-MB elevation without concomitant CK 
elevation was associated with a worse prognosis [18,19]. 
Although most of the previous studies showing the significance of CK(-MB) after 
MI are large-scale and incontrovertible, they are performed in patients with non-
ST-elevation ACS or STEMI for which thrombolytic or no reperfusion therapy was 
given. Theoretically, restoration of antegrade blood flow may influence the 
amounts of biomarkers release. Of the total CK in the myocardial infarct area, 
approximately 15% reaches the circulation in the absence of coronary 
recanalization. The remainder is hydrolysed either locally or in lymph [20]. As long 
as a predictable relationship exists between the amount of CK depleted and the 
amount that reaches the circulation, serial samples offer an estimate of the 
amount depleted and, therefore, an estimate of infarct size. But in animal models, 
reperfusion within 2 hours after coronary occlusion doubles the ratio of the 
amount of enzyme that is in the plasma compared with that depleted from 
myocardium [21]. Consequently, comparisons between reperfused and 
nonreperfused patients can be problematic [22]. Another study suggested also 
that CK-MB might overestimate infarct size after reperfusion [23]. 
However, as our analyses show, also in the era of primary PCI where TIMI-3 flow 
is achieved in the majority of patients, peak CK and CK-MB are still related to 
mortality and infarct size. Furthermore, in our analysis TIMI-3 flow after the 




Only 2 large-scale studies on prognostic importance of biomarkers were 
performed in patients undergoing primary PCI for STEMI. One-year mortality was 
well predicted by the cumulative extent of LDH in one study [12]. But, because of 
the slow release into the circulation compared to CK(-MB), cumulative LDH is not 
a very practical alternative and therefore not widely used for this purpose. Halkin 
et al showed that peak CK is an independent predictor of one-year mortality in a 
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post hoc analysis of the CADILLLAC trial [13]. This trial had several in- and 
exclusion criteria, influencing the external validity of the findings. Furthermore, 
only 73% of the included patients had available CK values, resulting in a selected 
group of patients with STEMI. 
 
Non-traditional markers 
After the redefinition of MI, troponin is the preferred biomarker to use in patients 
with (suspected) ACS [24]. Although there is some evidence that troponin can 
estimate infarct size [25], only studies with a limited sample size in patients 
following primary PCI have been performed, without reliable information in 
predicting mortality [26,27]. Myoglobin is rapidly released in the circulation and 
early estimation of the total extent of myocardial injury can be done, but because 
of the lack of cardiospecificity this marker is not used widely [28]. 
 
Study limitations 
Several limitations on our study have to be noted. During the 13 years of 
inclusion, techniques of PCI and medical treatment afterwards have been 
changed. This may have affected outcome, but seems to be unlikely affecting our 
principal conclusions. Although blood samples were taken every 8 hours, we did 
not calculate the area under the CK and CK-MB curve, another possible predictor 
of mortality after MI [7,8]. Furthermore, data on time to peak CK(-MB) are lacking. 
Moreover, as we collected blood samples until 24 hours after baseline and some 
patients might have their biomarker peak after this time window, possibly 
underestimating of peak CK(-MB) might have occurred in some patients. 
However, this seems to be unlikely, also according to others [13]. Finally, as a 
central role has been propagated last years for the cardiac troponins [24], these 
specific biomarkers potentially might have even more significance after primary 
PCI for STEMI [22]. 
 
Conclusion 
Our study shows an independent association between either peak CK or CK -MB 
and both LV function and mortality in patients undergoing primary PCI. 
Accordingly, the worldwide use of these two biomarkers seems to be justified, 
also in patients with TIMI-3 flow after mechanical reperfusion therapy. Future 
efforts should be aimed towards how to improve treatment in high-risk patients, as 
identified by peak CK(-MB). 
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Background: Although infarct location may predict prognosis after primary 
percutaneous coronary intervention (PCI) for ST elevation myocardial infarction 
(MI), previous studies were too small to demonstrate whether this association is 
independent of enzymatic infarct size or left ventricular ejection fraction (LVEF). 
 
Methods: A large scale, prospective, observational study was performed 
recording individual data from all patients who underwent primary PCI between 
1991 and 2004. Stratified analyses were performed according to enzymatic infarct 
size. The independent association between infarct location and one-year 
outcome, was compared with the prognostic importance of enzymatic infarct size 
and LVEF. 
 
Results: Of 4990 patients, 2485 (49.8%) had an anterior infarction. Patients with 
anterior MI had a significantly larger enzymatic infarct size (peak CK 2960 vs 
2009 U/l, p <0.001) and a lower mean LVEF (40.0% vs 50.0%, p <0.001). In all 
tertiles of enzymatic infarct size, patients with anterior MI had a lower LVEF. 
Mortality within one year was higher in patients with anterior infarction as well as 
in those with a high enzymatic infarct size or a low LVEF. Also, in all tertiles of 
enzymatic infarct size, patients with anterior infarction had a higher one-year 
mortality. After multivariable analyses, patients with anterior infarction still had an 
increased risk of a high enzymatic infarct size, a poor left ventricular function and 
also a higher one-year mortality, OR 1.35 (95%CI 1.07-1.70). However, low LVEF 
was a significant stronger predictor of one-year mortality, OR 4.4 (95%CI 2.4-7.8), 
compared to infarct size, OR 2.0 (95%CI 1.6-2.5) or anterior location, OR 1.6 
(95%CI 1.3-2.0). 
 
Conclusion: After primary PCI, location of infarction is still an important 
independent predictor of high enzymatic infarct size, low LVEF and increased 
mortality, even after adjusting for several clinical characteristics. However, LV 





In the pre-fibrinolytic and fibrinolytic era, it was shown that myocardial infarction 
(MI) involving the anterior wall was associated with increased myocardial cell 
death, reduced left ventricular (LV) ejection fraction and worse prognosis [1-4]. 
Apart from an increased amount of myocardial cell death after anterior infarction, 
also other factors may influence myocardial function and worse outcome in these 
patients [5-7], but most previous studies were too small to demonstrate the 
independent effect on prognosis of anterior MI.  
Primary percutaneous coronary intervention (PCI) has improved prognosis after 
ST elevation myocardial infarction (STEMI), particularly after anterior MI [8,9]. In 
patients undergoing primary PCI, the association between enzymatic infarct size 
and prognosis as well as between LV ejection fraction and prognosis was 
previously demonstrated [10,11]. Only one study examined in detail the impact of 
infarct location on prognosis after primary PCI, and this concerned an ad hoc 
analysis of data of a clinical trial, with many inclusion and exclusion criteria [7]. 
Therefore, the question remains whether infarct location is still an important 
predictor of mortality after primary PCI, particularly if compared with the 
prognostic importance of infarct size and LV-function. The primary aim of the 
present study was to evaluate whether location of MI has independent influence 







From January 1991 to December 2004, individual data from all patients with 
admission diagnosis of STEMI admitted for primary PCI at the Isala klinieken 
(Zwolle, the Netherlands) were prospectively recorded. To avoid double inclusion 
of patients, only the first recorded admission for STEMI during the study period 
was used. Patients were diagnosed with STEMI if they had chest pain of > 30 
minutes' duration with ST segment elevation > 2 mm in at least 2 precordials and 
> 1 mm in the limb leads. Before the primary PCI procedure, all patients received 
500 mg of aspirin intravenously, and 5000 IU intravenous heparin. Primary PCI 
was performed with standard techniques if the coronary anatomy was suitable for 
angioplasty. PCI success was determined by the classification system of the 
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Thrombolysis in Myocardial Infarction (TIMI) trial, in which a grade 3 blood flow 
indicates normal flow within the vessel, in combination with a myocardial blush 
grade 2 and 3 [12]. Additional treatment with glycoprotein IIb/IIIa-inhibitors or 
stents was at the discretion of the treating cardiologist. All patients were treated 
with optimised drug-therapy including angiotensin-converting enzyme inhibitors, 
β-blockers, aspirin and lipid-lowering drugs where appropriate. During the 




The infarct location was categorized into two groups: anterior location and non-
anterior location according to the admission electrocardiogram. Patients with a 
new left bundle branch block were classified as anterior MI. Protocol-specified 
blood sampling for creatine kinase (CK) and the muscle-brain fraction (CK-MB) 
levels was performed at baseline and at 8 hours, 16 hours and 24 hours after the 
index PCI. Measurement of serum total CK and CK-MB levels was performed 
according to local hospital standards. A large enzymatic infarct size was defined 
as patients who had CK release in the highest tertile. LV ejection fraction was 
measured before discharge by radionuclide ventriculography or by 
echocardiography if the patient had atrial fibrillation. A severely depressed LV 
ejection fraction was defined as an ejection fraction < 30%. 
 
Data collection and follow-up 
We collected the following variables from the patient files: age, gender, history of 
hypertension, diabetes, hyperlipidemia, and smoking, previous myocardial 
infarction, angiographic variables, laboratory measurements, pre-discharge LV 
function and discharge medication. Follow-up information was obtained from the 
patient's general physician or by direct telephone interview with the patient. 
Events were confirmed by reviewing the concerning letter to the general physician 
or patient’s clinical file if necessary, and all cause mortality was reported. Re-MI 
was defined as anginal complaints with new CK(-MB) elevation and/or new Q-
waves on the electrocardiogram in follow-up. Study approval was obtained from 







Statistical analysis  
Statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were 
expressed as mean ± standard deviation and categorical data as percentage, 
unless otherwise denoted. Differences between continuous data were performed 
by students t test, and the chi-square or Fisher’s exact test were used as 
appropriate for dichotomous data. Multivariable logistic regression analysis was 
performed to test the independent association between infarction location and a 
high enzymatic infarction size or a low left ventricular function. Peak CK levels 
were divided into three equal tertiles to determine the prognostic importance of 
infarct location in infarctions of different enzymatic size. As anterior MI was 
present in almost half of patients, the medians of enzymatic infarct size and LV 
ejection fraction were used to compare the association between infarct location, 
enzymatic infarct size, LV ejection fraction and prognosis. Significant variables 
analyzed are reported with their respective odd ratios and 95% confidence 
intervals (CI). Cox proportional-hazards regression models were used to estimate 
hazard ratios of infarction location with regard to survival at one year. For all 
analyses, statistical significance was assumed when the two-tailed probability 





Baseline characteristics  
During the study period, 5030 patients were included. Data on infarct location 
were available in 4990 patients (99%) and these patients were the study 
population. Mean age was 61.2 ± 11.9 years (range 19-94 years) and 24% were 
female. Data on enzymatic infarct size were available in 4820 patients (97%) and 
on left ventricular ejection fraction in 2861 patients (57%). The mean ischemic 
time before admission was 3.9 ± 4.8 hours. Diabetes was documented before 
admission in 535 patients (10.8%). A total of 2485 patients (49.8%) had an 
anterior infarction. Differences of the baseline and treatment characteristics 
between patients with anterior infarct location and those with non-anterior infarct 
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Table 1: Baseline characteristics according to infarct location in 4990 pts who were admitted 
for primary PCI for ST-elevation MI.  
Variables     Anterior  Non-anterior            p-value 
      n = 2485  n = 2505 
Age, yr    61.0±12.2  61.5±11.5  0.17 
Female gender   23.0   24.6   0.17 
History of 
 MI    12.2   12.9   0.72 
 CABG    1.8   4.0   < 0.001 
 PCI    5.1   7.0   0.02 
 Stroke    3.6   3.1   0.60 
 Hypertension   29.3   28.1   0.63 
 Hyperlipidemia  18.6   23.1   < 0.001 
 Family  CVD   41.3   42.6   0.66 
 Smoke    48.7   48.8   0.71 
 Diabetes   11.5   10.1   0.31 
Referred from other hospital  51    33   < 0.001 
Killip class >1    12.9    8.6   < 0.001 
Patient delay, hr   4.0±5.1  3.7±4.5  0.02 
Door to balloon time <30 minutes 53   41.7   < 0.001 
Coronary angiography 
   Multi-vessel disease  48.0   59.6   < 0.001 
   TIMI 0 flow pre-PCI   59   66   < 0.001 
   Collaterals, Rentrop >0  41.8   50.2   < 0.001 
 Diameter infarct related  
 vessel (mm)    2.8±0.50  3.1±0.55  < 0.001 




Table 2. Treatment according to infarct location in 4990 pts who were admitted for primary 
PCI for ST-elevation MI. 
Variables     Anterior  Non-anterior            p-value 
      n = 2485  n = 2505    
Initial treatment 
   Primary PCI    90.5   92.5   0.01 
   Conservative   5.3   4.5   0.2 
   CABG    4.3   3.0   0.02 
TIMI 3 flow post-PCI   85   89   < 0.001 
Hospital stay (days)   5.3±6.8  5.1±6.2  0.23 
Discharge medication 
   Aspirin    87   94   < 0.001 
   Cumarins    17.1   6.0   < 0.001 
   Beta-blocker   81.8   82.5   0.79 
   Diuretics    14.6   9.6   < 0.001 
   ACE-inhibitors   69   34   < 0.001 
% or mean ± sd 
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Table 3:  Outcome according to infarct location in 4990 pts who were admitted for primary 
PCI for ST-elevation MI. 
Variables    Anterior  Non-anterior            p-value 
     n =  2485  n = 2505  
Mean LVEF (%)  40.0±12.3  50.0±9.5  < 0.001 
LVEF < 30%   25   2.9   < 0.001 
Peak CK (U/L)  2960±2926  2009±2191  < 0.001 
Large enzym. infarct size 42.1   22.6   < 0.001  
Peak CK-MB (U/L)  295±254  209±172  < 0.001 
Mortality 
   30 days   5.8   3.4   < 0.001 
   One year   8.8   5.8   < 0.001 
Re-MI or death 
   30 days   6.5   3.8   < 0.001 
   One year   13.2   9.4   < 0.001 
Re-PCI 
   30 days   6.3   6.1   0.76 
   One year   14.6   14.8   0.87   
CABG 
   30 days   8.1   7.7   0.54 
   One year   13.1   13.2   0.92 
Stroke 
   30 days   0.3   0.5   0.26 
   One year   0.9   1.0   0.91 




Patients with anterior MI had a significantly larger enzymatic infarct size and a 
lower LV ejection fraction (table 3). The unadjusted risk of a large enzymatic 
infarct size for patients with anterior location was 2.49 (95% CI 2.2 – 2.8). Also 
the prevalence of a severely depressed LV ejection fraction was much higher in 
those with anterior infarction location (25%) compared to patients with non-
anterior location (2.9%). Furthermore, in all tertiles of enzymatic infarct size, 
patients with anterior MI had a lower LV ejection fraction (figure 1). 
A total of 230 patients (4.6%) died within 30 days and 363 (7.3%) died within one 
year after admission. Both a large enzymatic infarct size, OR 2.1 (95% CI 1.70 – 
2.60) and a severely depressed LV ejection fraction, OR 5.48 (95% CI 3.52 – 
8.53) were associated with increased one-year mortality. A large enzymatic infarct 
size was a predictor of one-year mortality in both patients with anterior MI, OR 
2.07 (95% CI 1.46 – 2.92) and in those with non-anterior MI, OR 1.91 (95% CI 
1.44 – 2.53). A severely depressed LV ejection fraction was also a predictor of 
one-year mortality in both patients with anterior MI, OR 5.62 (95% CI 3.11 – 
10.15) and those with a non-anterior MI, OR 6.84 (95% CI 2.63 – 17.83). 
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One-year mortality in patients with anterior location was 8.8% compared to 5.8% 
in those with non-anterior infarction (p <0.001). Survival curves of patients with 
anterior and non-anterior infarction are depicted in figure 2. 
 
The unadjusted risk of one-year mortality for patients with anterior location 
compared to non-anterior location was 1.56 (95% CI 1.26 – 1.92). The 
combination of death or re-MI was observed in 565 patients (11.3%) after one 
year. This combined endpoint was also higher in patients with anterior infarct 
location (table 3). Although not significant, a comparable trend for a higher 
mortality in patients with anterior infarction was seen in every tertile of enzymatic 

















P <0.001 P <0.001 P <0.001 









Figure 2. One-year mortality in 2485 patients with anterior infarct location and 2505 patients 
with non-anterior location. 
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Figure 4. Age and gender adjusted odds ratios for one-year mortality with regard to LV 





After adjusting for differences in age, gender, diabetes, previous MI, heart failure 
on admission, hypercholesterolemia and enzymatic infarct size, patients with 
anterior infarct location still had an increased risk of a severely depressed LV 
ejection fraction, OR 10.2 (95% CI 7.2 – 14.6). After adjusting for differences in 
age, gender, diabetes, previous MI, heart failure on admission and 
hypercholesterolemia, patients with anterior infarct location had also still an 
increased risk of a large enzymatic infarct size, OR 2.44 (95% CI 2.14 – 2.78). 
After adjusting for differences in age, gender, diabetes, previous MI, heart failure 
on admission, hypercholesterolemia and even enzymatic infarct size, patients 
with anterior infarct location had also still a significant increased risk of one-year 
mortality, OR 1.35 (95% CI 1.07 – 1.70). 
 
Comparison of prognostic importance 
To compare the prognostic importance, patients with anterior MI (50% of patients) 
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<46%), and with those with enzymatic infarct size higher than the median (CK 
>1729 U/L). The odd ratios, corrected for age and gender, for one-year mortality 
were 1.6 (95% CI 1.3 – 2.0) of anterior location, 2.0 (95% CI 1.6 – 2.5) of 
enzymatic infarct size and 4.4 (95% CI 2.4 – 7.8) of LV ejection fraction, and are 





Our results show that in patients undergoing primary PCI for STEMI, location of 
infarction is still an important independent predictor of a large enzymatic infarct 
size, low LV ejection fraction and increased mortality, even after adjusting for 
several clinical characteristics. In all tertiles of enzymatic infarct size, patients with 
anterior MI have a lower LV ejection fraction and an increased one-year mortality. 
LV ejection fraction is, however, a stronger predictor of mortality compared to 
infarct location or enzymatic infarct size. 
 
Previous studies 
Several studies have investigated the relation between infarct location, infarct 
size, LV ejection fraction and prognosis. However, most of these studies were 
performed in patients treated with thrombolytics or no reperfusion therapy at all. In 
patients not receiving reperfusion therapy, it was demonstrated that both peak 
enzyme level and infarct location had a poor in-hospital and long-term prognosis 
[1-3,13], although the effect of infarct location on long-term prognosis has been 
discussed [14,15]. 
If enzymatic infarct size is comparable, the effects on LV function seem to be 




After primary PCI, it was shown that both enzymatic infarct size, as defined by 
peak CK or peak CK-MB, and LV ejection fraction were related to prognosis 
[10,11]. Our study confirmed these findings. 
A study with gated single-photon emission computed tomography (SPECT) 
showed a lower LV ejection fraction for anterior infarctions than for inferior or 
lateral infarctions of the same extent [5]. Also in another study, left anterior 
descending artery (LAD)-related infarctions, when compared with non-LAD-
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related infarctions, had a lower residual LV ejection fraction for a similar amount 
of myocardial necrosis as determined by enzymatic infarct size [6]. A post-hoc 
analysis of the CADILLLAC trial demonstrated an association between infarction 
involving the LAD and a reduced LV function, less frequent collateral flow, 
impaired myocardial perfusion and increased major adverse cardiac events after 
one year [7]. However, this trial had a number of in- and exclusion criteria, 
influencing the external validity of the findings, and they did not adjust for 
enzymatic infarct size. 
 
A remarkable observation of a sub-analysis of the MADIT II trial was recently 
published, showing in patients with advanced LV dysfunction that inferior wall MI 
was associated with a significantly higher risk of mortality than anterior wall MI 
[17]. However, most patients included in MADIT II had their infarction very long 
before inclusion and the type of reperfusion therapy was not clear in that study. 
Possibly, progressive coronary artery disease with additional myocardial infarction 
may have contributed to the poor prognosis of inferior infarctions. 
 
Possible mechanisms 
There may be several reasons for the association between infarction location and 
prognosis. Anterior MI may be associated with a larger mass of infarcted 
myocardium [1]. However, both our study and previous studies [1-3,18] show also 
an association between location and prognosis after correction for enzymatic 
infarct size. 
 
Possibly, specific intrinsic and extrinsic qualitative differences between the 
myocardial wall regions are important [19]. Patients with anterior MI have a 
greater risk of expansion, regional dilatation and thinning of the infarct zone, 
leading to ventricular aneurysm, which, apart from the increased risk of thrombus 
formation and myocardial rupture, has an adverse effect on LV function [20]. This 
higher risk of aneurysm may be caused by a thinner myocardial wall at the apex 
by less circumferential fibres of the middle myocardial layer [21]. Therefore, apical 
involvement may result in greater systolic dysfunction per unit area infarcted [16]. 
Although a patent infarct-related artery has a favourable effect on LV remodelling 
[22] and is achieved in the majority of patients treated with PCI [23], LV 
remodelling remains common after anterior MI, despite the use of angiotensin-




Another possible reason for the poor prognosis after anterior MI is the potential 
disturbance in electromechanical behaviour, with septal incoordination after 
anterior MI [27]. Occurrence of bundle branch block or other intraventricular 
conduction defects may also influence prognosis [1,17]. 
 
Furthermore, differences in reperfusion may also explain the difference in 
outcome between anterior and inferior infarction. It was suggested that 
spontaneous reperfusion occurs more often in patients with non-anterior infarction 
[7], but this was not confirmed by our study. TIMI-3 flow post-PCI was more 
common in non-anterior MI in both our study and previous studies [7]. This and 
the lower prevalence of collaterals in anterior MI may contribute to less 
improvement in LV function [28]. 
 
Limitations 
During the 11 years of inclusion, techniques of PCI and medical treatment 
afterwards have been changed. Although this may have affected outcome, it 
seems unlikely to affect our principal conclusions. Another limitation is the 
selection of patients in the first years of registry, as patients with anterior 
infarction were more often accepted for primary PCI from referral hospitals in that 
period. Our follow-up period was only one year. Furthermore, we had no data on 
death causes or data of medication changes during follow-up. 
 
Conclusion 
Although not as strong as LV ejection fraction, location of infarction is still an 
important independent predictor of prognosis in patients undergoing primary PCI. 
The question remains whether the prognosis of patients with anterior MI could be 
improved by more aggressive medical treatment or by using more often 
prophylactic implantable defibrillators. 
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This thesis addresses the clinical value of systematic measurements of cardiac 
biomarkers after percutaneous coronary interventions (PCI). The importance of 
troponin T (TnT), creatine kinase (CK) and its muscle-brain isomer (CK-MB) is 
evaluated in patients undergoing elective PCI as well as in patients undergoing 
primary PCI for ST-elevation myocardial infarction (STEMI). 
 
The first chapter starts with an introduction and overview of this thesis. The 
number of PCIs has increased during the past decades and research on quality 
control and clinical implications is mandatory. 
Part I of this thesis is focused on myocardial injury and the measurement of 
cardiac biomarkers after elective PCI. 
In the second chapter, we describe the findings of a prospective study on 713 
unselected patients with elective PCI. TnT elevation (21%) occurred more often 
than CK elevation (9%). After a mean follow-up period of 10.9 months, 
postprocedural TnT, but not CK, was significantly associated with the primary 
combined endpoint of adverse cardiac events. In conclusion, increase of TnT 
after elective PCI has stronger prognostic implications when compared to 
increase of CK. 
We assessed the influence of pre-treatment with clopidogrel on the incidence of 
minor postprocedural TnT elevations in the third chapter in a prospective, 
observational study on 656 patients undergoing elective PCI. TnT was elevated in 
34% of the 330 patients without pre-treatment, compared to 30% of the 326 pre-
treated patients. After multivariable analyses, patients who were pre-treated with 
clopidogrel had a significantly lower risk of postprocedural TnT elevation (OR 
0.69, 95% CI 0.49-0.99). This effect was found in particular in those with older 
age, previous PCI, angina CCS 4 and multivessel disease. We concluded that, 
combined with results of other studies, pre-treatment with clopidogrel should be 
advised in patients waiting for elective PCI. 
In the fourth chapter we describe that patients with elective PCI undergoing 
multivessel PCI, compared to those undergoing single-vessel PCI, more often 
had TnT elevation after PCI (31.5 vs. 18.3%, p=0.001). Furthermore, there was a 
higher incidence of cardiac events during a mean follow-up period of 10.9 
months, in those undergoing a multivessel PCI. However, when in a multivariate 
model correction for the presence of multivessel disease itself was made, this 
association was not significant anymore. We could conclude that multivessel PCI 
was associated with more TnT release and that there was a trend towards a 
higher incidence of cardiac events during follow-up. 
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We present the results of a meta-analysis in the fifth chapter, including 20 
studies involving 15,581 patients undergoing elective PCI. Overall, troponin was 
elevated after PCI in 32.9% of patients. After a mean follow-up period of 16.3 
months, mortality was higher in patients with postprocedural troponin elevation 
compared to those without troponin elevation (4.4 vs. 3.3%, p=0.001). 
Furthermore, the combined endpoint of mortality or non-fatal myocardial infarction 
(MI) occurred more often in patients with troponin elevation (8.1 vs. 5.2%, 
p<0.001). According to this meta-analysis, troponin elevation after elective PCI 
provides important prognostic information. 
 
Part II of this thesis is focused on myocardial injury and the measurement of 
cardiac biomarkers in patients treated with primary PCI. 
A study investigating the value of TnT on admission in 444 patients undergoing 
primary PCI for STEMI is described in the sixth chapter. Elevation of TnT on 
admission was present in 47% of patients. Presentation delay, anterior MI 
location and higher age were independent predictors of elevated cTnT on 
admission. Furthermore, patients with TnT elevation on admission were less likely 
to have successful primary PCI compared to those without TnT elevation on 
admission and had significantly higher rates of one-year mortality. 
The results of a study on the prognostic importance of CK and CK-MB in 4,670 
patients undergoing primary PCI for STEMI are presented in the seventh 
chapter. Both increased CK and CK-MB were associated with a lower left 
ventricular ejection fraction (LVEF). One-year mortality was 5.4% and both peak 
CK and CK-MB were higher in those who died. Patients in the highest tertile of 
either peak CK or CK-MB had, also after multivariable analyses, a higher one-
year mortality, whereas the differences between the two lower tertiles were not 
significant. We concluded that, in patients undergoing primary PCI, peak CK and 
CK-MB are independent predictors of LVEF and mortality. 
In the eighth chapter, we assess the comparative predictive value of infarct 
location, infarct size and ejection fraction after primary PCI for STEMI. Low LVEF 
was a stronger predictor of one-year mortality (OR 4.4) compared to enzymatic 
infarct size (OR 2.0) or anterior location (OR 1.6). In addition, even after 
correction for enzymatic infarct size in multivariable analyses, patients with 
anterior infarction still had an increased risk of a poor LVEF and also a higher 
one-year mortality. In conclusion, although not as strong as LVEF, infarct location 






Many patients with coronary artery disease are nowadays treated with PCI and it 
is the most frequently performed revascularisation therapy [1]. The number of 
PCIs is still rising over the last years, and a further growth may be expected [2]. 
The recently published COURAGE trial showed no difference in the occurrence of 
major cardiovascular events in follow-up between an initial interventional 
approach compared to an initial conservative strategy in patients with stable 
angina pectoris [3]. However, this seems to be a very low-risk population, as most 
patients had minimal or no angina, a well preserved LVEF, and patients with a 
markedly positive stress test were excluded. Also, an improvement in angina-free 
status and a reduction in the requirement for subsequent revascularisation was 
observed in the patients in the interventional arm in that study [4]. As improving 
quality of life, and not improving survival, was already the main reason for 
performing PCI in patients with stable angina, this trial will probably not have 
many influence on the number of PCIs in these patients. Moreover, since invasive 
treatment has been shown to improve prognosis in patients with ST-elevation 
acute coronary syndromes (ACS) [5] as well as non-ST-elevation ACS [6], and 
the fact that there still seems to exist a risk-averse instead of a risk-driven 
strategy in daily practise in patients with ACS [7], the expected further rise in the 




Since the primary goal of elective PCI is to improve quality of life, particularly by 
reducing anginal complaints, it is important to reduce complications and side-
effects to a minimum. STEMI occurs rarely in patients undergoing elective PCI, 
with reported rates of less than 0.5% [8], but is a serious complication, and the 
development of new Q-waves has been associated with a worse prognosis [9]. 
Non-STEMI after elective PCI is more common and is also related to cardiac 
events during follow-up. This has been shown for minor myocardial injury, as 
measured by elevations of CK(-MB) and especially troponin according to our 
analyses. 
The measurement of postprocedural biomarker release, especially elevation of 
troponin, seems therefore suitable to monitor PCI success when applying new 
techniques and medications. Reduced postprocedural biomarker release has 
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been shown after treatment with glycoprotein IIb/IIIa inhibitors [10,11], clopidogrel 
[12], statins [13] or adenosine [14]. 
Whether patients with postprocedural biomarker release might benefit of more 
aggressive medical therapy (e.g. increasing or adding beta-blockers, ACE-
inhibitors and/or lipid-lowering drugs) or a lower threshold for re-angiography, has 
to be investigated. 
 
Primary PCI 
Apart from the ECG at admission, cardiac enzymes and especially troponin at 
admission are helpful to identify patients with a worse prognosis in those 
undergoing primary PCI for STEMI [15,this thesis]. This can be in part explained 
by a longer delay in these patients, and early diagnosis and reperfusion therapy 
are very important. Efforts to improve prognosis of patients with increased TnT at 
admission should be made, and the use of glycoprotein IIb/IIIa inhibitors for 
instance has been associated with improved myocardial perfusion in patients with 
elevated troponin levels at admission and TIMI-3 flow post-PCI [16]. 
According to this thesis, peak values of CK and CK-MB predict prognosis in 
patients treated with primary PCI. Therefore, these enzymes may stratify patients 
for additional therapies. For example, cardiac enzymes might be superior, 
possibly next to LVEF, infarct location and other variables, in selecting patients 
with potential benefit of implantable defibrillators, whereas a low LVEF is 
nowadays practically the only used criterion [17]. 
The cardiac troponins are potentially superior again, when compared to CK(-MB), 
in estimating infarct size and especially predicting prognosis in patients 
undergoing primary PCI. However, limited studies have been performed on this 
issue, focusing on late, single values of troponin [18,19]. Therefore, further 




Brain natriuretic peptides (BNP and/or NT-pro-BNP) are helpful for the detection 
of congestive heart failure [20]. Although elevations of BNP are prognostic for 
death in patients with ACS, and women presenting with normal troponin but 
elevated BNP values may benefit from early PCI [21], the preferred strategy in the 
individual patient with ACS remains unclear [22]. The admission value of BNP has 
been reported to be an independent predictor of short-term death and 
angiographic success after PCI in patients with STEMI [23]. Furthermore, pre-
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procedural BNP in patients undergoing PCI for stable angina or non-ST-elevation 
ACS provides independent prognostic information during follow-up [24]. 
Moreover, postprocedural BNP has recently been associated with postprocedural 
CK-MB as well as with TnT levels, probably as a result of hemodynamic stress 
[25]. Whether a rise of BNP after elective PCI is also associated with prognosis 
has yet to be investigated. 
 
C-reactive protein (CRP) levels have been associated with the extend of 
inflammatory state of atherosclerosis in patients with coronary artery disease. In 
patients with stable coronary disease or acute coronary syndromes, CRP 
measurement may be useful as an independent marker for assessing likelihood of 
recurrent events [26]. CRP has been related to infarct size and mortality after 
primary PCI for STEMI [18]. However, after multivariable analysis only troponin 
level and Killip-class were independent predictors of mortality in that study. 
Increase of CRP level after elective PCI may also have prognostic value [27,28]. 
 
Heart-type fatty acid binding protein (H-FABP) is a promising biomarker that is 
released rapidly from the cardiomyocyte in response to myocardial injury. It has 
comparable kinetics and release as myoglobin, but is more cardiospecific [29]. 
Recently, H-FABP was shown to provide significant incremental information for 
risk stratification in patients with ACS, independent of troponin, BNP and 
myoglobin [30]. H-FABP can be used as a marker of reperfusion success in 
STEMI patients treated with thrombolytics [31], as well as in patients undergoing 
primary PCI [32]. There are no data on the prognostic value of H-FABP after 
elective PCI. Possibly, it can be useful in patients who are planned to be 
discharged early, although it has been suggested that this can be safe using only 
patient symptoms, angiographic results and ECG, without biomarkers as selection 
criteria [33]. Future studies should demonstrate potential benefits of this 
biomarker. 
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In dit proefschrift wordt het belang van myocardiale schade rondom percutane 
coronaire interventies (PCI) onderzocht. De waarde van de cardiale markers 
troponine T (TnT), creatine kinase (CK) en diens MB-isomeer (CK-MB) wordt 
geëvalueerd bij zowel patiënten die electieve PCI procedures ondergaan, als bij 
patiënten die primaire PCI ondergaan vanwege een ST-elevatie myocardinfarct 
(STEMI). 
 
Het eerste hoofdstuk geeft een algemene inleiding en beschrijft de inhoud van 
het proefschrift. Het aantal PCI’s is de laatste decennia sterk toegenomen en 
onderzoek met betrekking tot kwaliteitscontrole en klinische consequenties is 
noodzakelijk. 
Deel I van dit proefschrift is gericht op myocardiale schade en stijging van 
cardiale markers na een geplande PCI. 
In het tweede hoofdstuk worden de resultaten van een prospectieve studie met 
713 ongeselecteerde patiënten beschreven die een electieve PCI ondergingen. 
Na de procedure was er vaker stijging van TnT (21%) dan van CK (9%). Na 
gemiddeld 11 maanden bleek een postprocedurele stijging van TnT, maar niet 
van CK, significant geassocieerd met het gecombineerde primaire eindpunt van 
ongunstige cardiale gebeurtenissen. Op grond hiervan werd geconcludeerd dat 
stijging van TnT na een electieve PCI meer prognostische betekenis heeft in 
vergelijking met stijging van CK. 
In een prospectieve, observationele studie met 656 patiënten die een electieve 
PCI kregen, onderzochten wij de invloed van voorbehandeling met clopidogrel op 
het voorkomen van lichte postprocedurele TnT-stijging, en beschrijven dit in het 
derde hoofdstuk. TnT was verhoogd bij 34% van de 330 patiënten zonder 
voorbehandeling versus 30% van de 326 patiënten met voorbehandeling. Na 
multivariabele analyse bleek dat patiënten die werden voorbehandeld met 
clopidogrel een significant lagere kans hadden op postprocedurele TnT-stijging. 
Dit effect werd met name gevonden bij patiënten die ouder waren, reeds eerder 
een PCI ondergingen, instabiele angina pectoris of meervatslijden hadden. Wij 
concludeerden dat, mede gezien de resultaten van andere studies, 
voorbehandeling met clopidogrel geadviseerd zou moeten worden bij patiënten 
die wachten op een electieve PCI. 
In het vierde hoofdstuk beschrijven wij dat patiënten die een electieve PCI van 
meerdere vaten ondergingen, vaker TnT-stijging na de procedure hadden in 
vergelijking met patiënten die een electieve PCI van één vat ondergingen (31.5 
vs. 18.3%). Bovendien hadden patiënten, na een PCI van meerdere vaten, vaker 
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ongunstige cardiale gebeurtenissen na een follow-up duur van gemiddeld 10.9 
maanden, alhoewel bleek dat wanneer er gecorrigeerd werd voor meervatslijden 
dit verschil niet meer significant was. Wij concludeerden dat PCI van meerdere 
vaten geassocieerd is met vaker TnT-stijging na de procedure en een verhoogd 
risico op ongunstige cardiale gebeurtenissen. 
We presenteren in het vijfde hoofdstuk de resultaten van een meta-analyse van 
20 studies met in totaal 15.581 patiënten die een electieve PCI ondergingen. 
Troponine was verhoogd na de procedure bij 32.9% van de patiënten. Na een 
gemiddelde follow-up periode van 16.3 maanden was de mortaliteit hoger bij 
patiënten met een verhoogd troponine in vergelijking met patiënten zonder een 
verhoogd troponine na de procedure (4.4 vs. 3.3%). Bovendien was het 
gecombineerde eindpunt van mortaliteit en/of myocardinfarct in follow-up vaker 
behaald bij patiënten met een verhoogd troponine (8.1 vs. 5.2%). Volgens deze 
meta-analyse levert troponine na een electieve PCI belangrijke prognostische 
informatie. 
 
Deel II van dit proefschrift is gericht op myocardiale schade en het bepalen van 
cardiale markers bij patiënten die behandeld worden met primaire PCI vanwege 
STEMI. 
In het zesde hoofdstuk wordt een studie met 444 patiënten beschreven waarbij 
gefocust werd op de eerst gemeten TnT bij opname. Een verhoogd TnT bij 
opname werd gevonden bij 47% van de patiënten. Een late presentatie, 
voorwandinfarct en een oudere leeftijd waren onafhankelijke voorspellers van een 
verhoogd TnT bij opname. Bovendien hadden patiënten met een verhoogd TnT 
bij opname, in vergelijking met diegenen met een normaal TnT bij opname, 
minder vaak een succesvolle primaire PCI en een verhoogde één-jaarsmortaliteit. 
De prognostische waarden van CK en CK-MB werden onderzocht in een studie 
met 4670 patiënten die een primaire PCI ondergingen wegens een STEMI, zoals 
beschreven wordt in het zevende hoofdstuk. Zowel een verhoogd CK als een 
verhoogd CK-MB waren geassocieerd met een lagere linker ventrikel 
ejectiefractie (LVEF). De totale één-jaarsmortaliteit was 5.4%, en zowel de piek 
CK als de piek CK-MB waren hoger bij diegenen die overleden. Patiënten in het 
hoogste tertiel van zowel piek CK als piek CK-MB hadden, ook na multivariabele 
analyse, een hogere één-jaarsmortaliteit, terwijl de verschillen tussen de twee 
lagere tertielen niet significant waren. Wij concludeerden dat bij patiënten die een 
primaire PCI ondergaan, piek CK en piek CK-MB beide onafhankelijke 
voorspellers zijn van LVEF en mortaliteit. 
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In het achtste hoofdstuk werd de prognostische waarde van infarctlocatie, 
infarctgrootte en LVEF na een primaire PCI bestudeerd. Een lage LVEF was een 
duidelijkere voorspeller van één-jaarsmortaliteit (OR 4.4) in vergelijking met 
enzymatische infarctgrootte (OR 2.0) en voorwandlocatie (OR 1.6). Daarnaast 
bleek dat patiënten met een voorwandinfarct, ook na correctie voor enzymatische 
infarctgrootte, een verhoogde kans hadden op het ontwikkelen van een slechte 
LVEF en een verhoogde één-jaarsmortaliteit. Concluderend blijkt infarctlocatie, 
alhoewel niet zo krachtig als LVEF, een belangrijke onafhankelijke voorspeller te 






Veel patiënten met coronaire hartziekte worden tegenwoordig behandeld met een 
PCI en dit is tevens de meest gebruikte coronaire revascularisatie-behandeling. 
Het aantal verrichte PCI’s neemt de laatste jaren nog steeds toe en een verdere 
toename wordt verwacht. Het recent gepubliceerde COURAGE onderzoek liet 
geen verschil zien, in harde cardiale eindpunten gedurende follow-up, tussen 
aanvankelijk conservatief in vergelijking met aanvankelijk invasief behandelde 
patiënten met stabiele angina pectoris. Doch de patiëntengroep van deze studie 
betreft een zeer lage risicopopulatie, daar de meeste patiënten geen of slechts 
geringe angina pectoris klachten hadden, een goede LVEF hadden en patiënten 
met een sterk positieve inspanningstest geëxcludeerd werden. Bovendien bleken 
de patiënten in de aanvankelijk invasief behandelde groep wel vaker vrij te blijven 
van angina pectoris en minder vaak revascularisatie-behandelingen in de follow-
up periode nodig te hebben. Omdat verbetering van de kwaliteit van leven en niet 
verlenging van de levensduur al de voornaamste reden is om een electieve PCI 
te verrichten, zal deze studie het jaarlijks aantal verrichte PCI’s waarschijnlijk niet 
sterk beïnvloeden. De levensverwachting van patiënten met zowel ST-elevatie als 
non-ST-elevatie acute coronaire syndromen (ACS) kan wel verbeterd worden met 
een invasieve behandeling. Daar ook gebleken is dat patiënten met een ACS nog 
steeds te weinig invasief behandeld worden, lijkt de verwachte verdere stijging 
van het aantal jaarlijks te verrichten PCI’s aannemelijk, vooral voor behandeling 
van patiënten met een ACS. 
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Electieve PCI 
Aangezien het belangrijkste doel van een electieve PCI verbeteren van de 
kwaliteit van leven is, vooral door het verminderen van angineuze klachten, is het 
belangrijk om complicaties en bijwerkingen van de interventie tot een minimum te 
beperken. Er ontstaat zelden een STEMI als gevolg van een electieve procedure 
(ca 0.5%), maar het is een ernstige complicatie en het ontstaan van Q-golven op 
het ECG is geassocieerd met een slechte prognose. Non-STEMI ontstaat vaker 
na een electieve PCI en is ook geassocieerd met cardiale gebeurtenissen in 
follow-up. Dit is bewezen voor geringe myocardiale schade zoals bepaald met 
CK(-MB) en ook voor troponine zoals onze analyses laten zien. 
Het meten van postprocedurele enzymuitstoot, vooral de verhoging van 
troponine, lijkt daarom bruikbaar om het succes van een PCI te beoordelen als er 
een nieuwe techniek toegepast of medicatie gebruikt wordt rondom een PCI. Het 
zou ook gebruikt kunnen worden voor kwaliteitscontrole. Verlaging van de 
postprocedurele enzymuitstoot is gezien bij gebruik van glycoproteine IIb/IIIa 
remmers, clopidogrel, statines en adenosine. 
Of patiënten met minimale myocardiale schade na een electieve PCI ook baat 
hebben bij een agressievere medicamenteuze behandeling of een lagere drempel 
voor re-angiografie, moet nog onderzocht worden. 
 
Primaire PCI 
Van de patiënten die een primaire PCI vanwege STEMI ondergaan, zijn naast het 
ECG ook cardiale enzymen en met name troponine bij opname in staat om 
patiënten met een slechtere prognose te identificeren. Dit kan deels verklaard 
worden door een latere presentatie, en vroege diagnose en reperfusietherapie 
zijn erg belangrijk. Pogingen om de prognose van patiënten met een verhoogd 
troponine bij opname te verbeteren zijn nodig. Het gebruik van glycoproteine 
IIb/IIIa remmers is bijvoorbeeld al geassocieerd met een betere myocardiale 
perfusie bij patiënten met een verhoogd troponine (bij opname) en TIMI-3 flow na 
de procedure. 
Volgens dit proefschrift voorspellen piekwaarden van CK en CK-MB de prognose 
van patiënten die behandeld zijn met een primaire PCI. Deze enzymen zijn 
daarom mogelijk bruikbaar om patiënten te stratificeren naar aanvullende 
behandelingen. Wellicht zijn cardiale enzymen, in combinatie met infarctlocatie, 
LVEF en andere variabelen, superieur bij het selecteren van patiënten met een 
voordeel van het implanteren van defibrillatoren, terwijl thans in de praktijk een 
lage LVEF bijna het enige gebruikte selectiecriterium is. 
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Cardiale troponines zijn mogelijk opnieuw superieur om, in vergelijking met CK(-
MB), infarctgrootte in te schatten en met name in het voorspellen van de 
prognose van patiënten die een primaire PCI ondergaan. Tot nu toe is er slechts 
een beperkt aantal studies gepubliceerd waarbij bovendien slechts één enkele 
late bepaling van troponine werd onderzocht. Daarom is verder onderzoek 
noodzakelijk met betrekking tot dit onderwerp, met ook aandacht voor de 
piekwaarden van troponine. 
 
 
Andere cardiale markers 
Het brain natriuretisch peptide (BNP) is bruikbaar bij het opsporen van hartfalen. 
Alhoewel verhogingen van het BNP ook prognostische betekenis hebben bij 
patiënten met een ACS, is het nog onduidelijk in hoeverre het de behandeling van 
de individuele patiënt met een ACS kan beïnvloeden. Het BNP bij opname is bij 
patiënten met een STEMI een onafhankelijke voorspeller van overlijden op korte 
termijn en angiografisch succes na een primaire PCI. Bovendien kan de pre-
procedurele waarde van het BNP ook prognostische informatie geven over 
patiënten die een PCI ondergaan vanwege stabiele angina pectoris of een non-
ST-elevatie ACS. Tevens is het postprocedureel BNP geassocieerd met zowel 
postprocedurele CK-MB als met TnT waarden, waarschijnlijk als gevolg van 
veranderingen in de hemodynamiek. Of een stijging van het BNP na een 
electieve PCI ook prognostische waarde heeft, moet nog worden onderzocht. 
 
C-reactief proteïne (CRP) is geassocieerd met de uitgebreidheid van de 
ontsteking bij atherosclerose van patiënten met een coronaire hartziekte. Zowel 
bij patiënten met stabiele coronaire hartziekte als bij diegenen met een ACS kan 
het CRP helpen om de kans in te schatten van een cardiale gebeurtenis in de 
toekomst. In één studie leek het CRP aanvankelijk gerelateerd aan de 
infarctgrootte en de mortaliteit bij patiënten die een primaire PCI ondergaan, doch 
na multivariabele analyse waren alleen troponine en Killip-klasse onafhankelijke 
voorspellers van mortaliteit. Stijging van het CRP na een electieve PCI lijkt echter 
ook een voorspellende waarde te hebben. 
 
Het heart-type fatty acid binding protein (H-FABP) is een veelbelovende cardiale 
marker die snel uit de myocardcel vrijkomt bij myocardiale schade. Het lijkt qua 
kinetiek en uitstootprofiel op myoglobine, maar is cardiospecifieker. Recent is 
aangetoond dat H-FABP significant toegevoegde waarde heeft bij de 
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risicostratificatie van patiënten met een ACS, onafhankelijk van troponine, BNP 
en myoglobine. H-FABP is bruikbaar als marker van reperfusiesucces bij 
patiënten met een STEMI, zowel bij behandeling met trombolyse als bij 
behandeling met primaire PCI. Er zijn geen gegevens over de prognostische 
waarde van H-FABP na een electieve PCI. Mogelijk is het H-FABP bruikbaar bij 
patiënten waarbij een vroeg ontslag uit het ziekenhuis gepland is. Recent is 
echter aangetoond dat dit vroege ontslag ook reeds veilig kan op geleide van 
symptomen, angiografisch resultaat en het ECG, zonder cardiale markers als 
selectiecriterium. Toekomstige studies zullen de potentiële voordelen van het H-
FABP moeten aantonen, maar het grootste voordeel is wellicht bij triage van 
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